

# SWISS BIOTECH DAY 2026

May 4-5, 2026  
Congress Center Basel

## Conference guide

Host and event manager:



Logistics and marketing partner:


**bamconn**

# Conference program at a glance

Monday, May 4, 2026

08:00-09:45	<b>Citeline pre-event</b> (by invitation only)	Room Osaka/Samarkand, level 3
09:30	Early bird badge pickup	Entrance CCB, level 0
10:00-11:00	<b>Swiss Biotech Association general assembly</b>	Room Singapore, level 2
11:00	Registration opens	Entrance CCB, level 0
11:00-11:45	<b>Media conference</b> (media only)	Room Mexico, level 2
11:00-18:45	Exhibition	Hall 4.0, level 0   Foyer, level 2 p. 57
11:00-18:00	Global Village, mentoring booths, Swiss cluster booths	Room San Francisco, level 3 pp. 24 + 64
11:00-18:45	Partnering	Hall 4.1, level 1 p. 7
11:30-13:30	Lunch	Hall 4.0, level 0   Foyer, level 2   Foyer, level 3 p. 7
12:30-14:00	<b>Plenary session I</b>	Room Montreal, level 2 p. 9
14:00-15:00	Coffee break	Hall 4.0, level 0   Foyer, level 2

## Parallel tracks




14:30-18:15 <b>Panels &amp; pitches</b> Room Delhi, level 0 p. 10	14:30-18:15 <b>Panels &amp; pitches</b> Room Kairo, level 0 p. 12	14:30-18:15 <b>Panels &amp; pitches</b> Room Shanghai 1+2, level 0 p. 14	14:30-18:15 <b>Panels &amp; pitches</b> Room Shanghai 3+4, level 0 p. 16
14:30-15:15 <b>Pitch digital chapter</b> p. 10	14:30-15:15 <b>Panel 1 - Clario</b> p. 12	14:30-15:15 <b>Panel 2 - Deloitte</b> p. 14	14:30-15:15 <b>Panel 3 - KPMG</b> p. 16
15:30-16:15 <b>Panel 4 - SOPHiA Genetics</b> p. 10	15:30-16:15 <b>Panel - Lonza</b> p. 12	15:30-16:15 <b>Panel 5 - Tibio</b> p. 14	15:30-16:15 <b>Panel 6 - Swiss-Japanese</b> p. 16
16:15-17:00 <b>Poster presentations</b>  Hall 4.1, level 1   Foyer, level 3 p. 66			
16:30-17:15 <b>Panel 7 - Citeline</b> p. 11	16:30-17:15 <b>Panel 8 - talent chapter</b> p. 13	16:30-17:15 <b>Panel 9 - IQVIA / PharmaBiome</b> p. 15	16:30-18:15 <b>Pitch - Emerging Swiss biotech champions</b> p. 17
17:30-18:15 <b>Panel 10 - Zühlke</b> p. 11	17:30-18:15 <b>Panel 11 - Cetacea / Metronomia</b> p. 13	17:30-18:15 <b>Panel 12 - Cohesion Bureau</b> p. 15	
18:00-18:45	International reception of the Global Village San Francisco, level 3 p. 29		
18:45-21:00	Evening reception Hall 4.0, level 0   Foyer, level 2   Foyer, level 3		



Sunday, May 3, 2026

17:30-20:30	Welcome reception	Markthalle Basel
-------------	-------------------	------------------

Kindly supported by    

14:30-16:30 <b>Emerging biotech company presentations</b> Room Singapore, level 2 p. 18 	14:30-18:15 <b>Clinical stage biotech company presentations</b> Room Montreal, level 2 p. 20 	14:30-18:15 <b>Commercial stage company presentations</b> Room Sydney, level 2 p. 21 	14:30-18:00 <b>Moderated networking tables</b> Room Rio, level 2 22	14:15-17:15 <b>Global Village</b> Room Osaka/Samarkand, level 3 32
			14:30-15:00 <b>Table 1 - Adimab</b> p. 22	14:15-15:00 <b>Plenary session</b> p. 32
			15:10-15:40 <b>Table 2 - Clinigen</b> p. 22	15:15-16:00 <b>Panel</b> p. 32
			15:50-16:20 <b>Table 3 - Impag</b> p. 23	16:15-17:15 <b>Pitch</b>
16:45-17:30 <b>Pitch - Nucleate</b> p. 19			17:10-17:40 <b>Table 4 - Sciensus</b> p. 23	
17:45-18:30 <b>Pitch - Venture leader</b> p. 19				

# Conference program at a glance


Tuesday, May 5, 2026

07:15	Registration opens	Entrance CCB, level 0
07:45-16:30	Partnering	Hall 4.1, level 1 p. 7
09:00-16:30	Exhibition	Hall 4.0, level 0   Foyer, level 2 p. 57
09:00-15:30	Global Village, mentoring booths, Swiss cluster booths	Room San Francisco, level 3 pp. 24 + 64

**09:00-09:45 Panel discussions & pitching sessions**

<b>Panel 13 - Aesara</b> Room Delhi, level 0 p. 37	<b>Panel 14 - PSI</b> Room Kairo, level 0 p. 40	<b>Panel 15 - Obelysq</b> Room Shanghai 1+2, level 0 p. 43	<b>Pitch - Curie.Bio</b> Room Shanghai 3+4, level 0 p. 46	<b>Panel 16 - FGK</b> Room Singapore, level 2 p. 49
--	---	---	---	---

10:00-12:00 **Plenary session II** Room Montreal, level 2 p. 36

12:00-14:00 Lunch  Hall 4.0, level 0 | Foyer, level 2 | Foyer, level 3 p. 7




**Parallel tracks**

12:15-16:45 <b>Panels &amp; pitches</b> Room Delhi, level 0 p. 37	12:15-16:45 <b>Panels &amp; pitches</b> Room Kairo, level 0 p. 40	12:15-16:45 <b>Panels &amp; pitches</b> Room Shanghai 1+2, level 0 p. 43	12:15-16:45 <b>Panels &amp; pitches</b> Room Shanghai 3+4, level 0 p. 46
12:15-13:00 <b>Pitch - industrial biotech</b> p. 37	12:15-13:00 <b>Panel 17 - BiomedVC</b> p. 40	12:15-13:00 <b>Pitch - lab automation</b> p. 43	12:15-13:00 <b>Panel 18 - Swiss Biotech Ass.</b> p. 46
13:00-13:45 <b>Panel 19 - BlancLabo</b> p. 38	13:00-13:45 <b>Panel 20 - CSL</b> p. 41	13:00-13:45 <b>Panel 21 - diagnostics</b> p. 44	13:00-13:45 <b>Panel 22 - WuXi App-Tec</b> p. 47
14:00-14:45 <b>Panel 23 - Homburger/Hoffmann</b> p. 38	14:00-14:45 <b>Panel 24 - Schellenberg Wittmer</b> p. 41	14:00-14:45 <b>Panel 25 - Livinovea</b> p. 44	14:00-14:45 <b>Panel 26 - Molecular Partners</b> p. 47
14:45-15:30 <b>Poster presentations</b>  Hall 4.1, level 1   Foyer, level 3 p. 66			
15:00-15:45 <b>Panel 27 - Verdeya</b> p. 39	15:00-15:45 <b>Panel 28 - WuXi XDC</b> p. 42	15:00-15:45 <b>Panel 29 - Solvias</b> p. 45	15:00-15:45 <b>Panel 30 - Siemens</b> p. 48
16:00-16:45 <b>Panel 31 - Baker McKenzie</b> p. 39	16:00-16:45 <b>Panel 32 - Syneos Health</b> p. 42	16:00-16:45 <b>Panel 33 - CinnaGen</b> p. 45	16:00-16:45 <b>Panel 34 - Viridis-Group</b> p. 48

15:30-16:30 Marketplace of the Global Village Room San Francisco, level 3 p. 29

16:45-18:30 Farewell reception Hall 4.0, level 0 | Foyer, level 2



12:30-16:45 <b>Emerging biotech company presentations</b> Room Singapore, level 2 p. 50	12:30-15:00 <b>Clinical stage biotech company presentations</b> Room Montreal, level 2 p. 51	12:30-16:45 <b>Commercial stage company presentations</b> Room Sydney, level 2 p. 52	12:10-15:20 <b>Moderated networking tables</b> Room Rio, level 2 53	12:15-15:15 <b>Global Village</b> Room Osaka/Sa-markand, level 3 34
			12:10-12:40 <b>Table 5 - Dinamiqs</b> p. 53	12:15-13:00 <b>Panel</b> p. 34
	15:15-16:00 <b>Investor pitch - Creadd</b> p.51		12:50-13:20 <b>Table 6 - Clinilabs</b> p. 53	13:15-14:15 <b>Pitch</b> p. 34
			Room Mexico, lev. 2: 14:50-15:20 <b>Table 7 - DataArt</b> p. 53	14:30-15:15 <b>Panel</b> p. 35

# Welcome reception

# Housekeeping notes

## Welcome reception

Markthalle Basel

**Sunday, May 3, 2026 | 17:30 - 20:30 | Markthalle Basel, Steinentorberg 20**

The Swiss Biotech Day will once again provide a platform in Basel for networking, engaging discussions, and the exploration of advancements in R&D, manufacturing, data management, artificial intelligence, and innovative financing.

This inaugural gathering provides a prime networking opportunity, allowing attendees to connect and engage with peers before the event officially starts. Join more than 1,500 other participants who have signed up for this reception for an aperitif and an informal fun networking evening in anticipation of the lively days ahead.

Kindly supported by    




Food will be served at the times and locations listed below. Beverages are available in all areas throughout the event.

**Monday, May 4, 2026**

Level 0	Level 2	Level 3
11:30 - 13:30 Lunch	11:30 - 13:30 Lunch	11:30 - 13:30 Lunch
		18:00 - 18:45 International reception
18:45 - 21:00 Evening reception	18:45 - 21:00 Evening reception	18:45 - 21:00 Evening reception

**Tuesday, May 5, 2026**

Level 0	Level 2	Level 3
12:00 - 14:00 Lunch	12:00 - 14:00 Lunch	12:00 - 14:00 Lunch
		15:30 - 16:30 Global Village market place
16:45 - 18:30 Farewell reception	16:45 - 18:30 Farewell reception	


You will find a **barista station at booth 61 in Hall 4.0** on level 0 for your much-needed daily dose of caffeine, kindly supported by 

### Pre-scheduled one-to-one meetings

Please check your individual meeting schedule for times and locations of your confirmed meetings. Need help? Please see the partnering help desk on level 1.

supported by 



Free WiFi - kindly supported by   
SSID: Free Messe Basel  
Login via SMS  
(one Login per device)

 **X**  
#swissbiotechday  
 **LinkedIn**  
#swissbiotechday

# SWISS+ BIOTECH™

Collaborate with us and use the power  
of our networking platforms

Save the date!



## Swiss Biotech Day: April 26-27, 2027

For international networking at one of the leading global biotech conferences, with thousands of guests



## Boosting global visibility

By promoting biotechs in the Swiss Biotech Directory, by disseminating their news, and with success stories



## Financing and partnering

By connecting Swiss R&D biotech companies with global investors and industry partners on Swiss Biotech Ventures



## Finding talent internationally

By matching Swiss job opportunities and talents on Swiss Biotech Orbit



## Foster international collaboration

By uniting foreign biotech clusters with the Swiss biotech ecosystem through our Global Village



## Professional development and education

At the Swiss Biotech Association Academy offered by academic institutions & regular Swiss Biotech Insight meetings

12:30-14:00 Plenary session I

Room Montreal, level 2

Moderation: **Monika Jones**

### 12:30 Welcome local host

**Kaspar Sutter**, Head of the Department of Economic, Social and Environmental Affairs, Canton of Basel-Stadt

### 12:35 Welcome organizer

**Michael Altorfer**, CEO, Swiss Biotech Association

### 12:45 Fireside session

**Thomas Schinecker**, CEO, Roche Group, and  
**Patrick Amstutz**, President of the Swiss Biotech Association

### 13:20 Business development panel

Host: **Frances Stocks Allen**, Partner Life Sciences, Cooley  
Panelists:

**Richard Girling**, Partner Life Sciences Investment Banking, Centerview  
**Jason Radford**, Senior Vice President Strategic Partnerships, BeOne Medicines  
**Dragan Grabulovski**, Chief Executive Officer, Araris

### 13:45 Swissmedic

**Vincenza Trivigno**, Executive Director, Swissmedic

## Panels &amp; pitches

Presented by  Swiss Biotech Association

14:30-15:15 Pitch

Room Delhi, level 0

**Digital and health technologies chapter: AI-driven breakthroughs from target to therapy**

This pitching session brings together a new wave of startups leveraging artificial intelligence, digital twins, and advanced biologics to transform therapeutics development. From target identification and validation to therapeutic design and clinical acceleration, these companies showcase how data-driven approaches and novel platforms are increasing speed, precision, and scalability. Covering applications spanning from oncology to aging and beyond, the session highlights how integrated digital and biological innovations are reshaping the future of healthcare.

Moderation: **Annamaria Kauzlaric**, Head of digital and health technologies chapter, Swiss Biotech Association

Jury: **Philippe Menu**, Chief Medical Officer & Chief Product Officer SOPHiA Genetics | **Sandra von Meier**, Head of Business Development Life Science, Terra Quantum | **Maria Escala-Garcia**, Investment Associate, VI Partners

14:30 Introduction

14:35 TwinEdge Bioscience

14:55 Glass Medical AI

14:40 Lemna Bio

15:00 Precise Health

14:45 Fy Cappa Biologics

15:05 Sydra

14:50 ALP AI

15:10 Voting and closing remarks

Presented by  SOPHiA GENETICS

15:30-16:15 Panel 4

Room Delhi, level 0

**Liquid biopsy at a tipping point in precision oncology**

Liquid biopsy is reaching a critical inflection point in precision oncology, yet its full potential remains largely untapped.

This panel explores how decentralized models, AI-powered analytics, and ecosystem-level collaborations are driving broader liquid biopsy adoption. Experts will trace the evolution of MSK-ACCESS® powered with SOPHiA DDM™ from an innovative in-house test to a globally scalable solution and examine how the shared vision between SOPHiA GENETICS and MSK has the potential to transform the future of precision oncology.

Moderation: **Philippe Menu**, Chief Medical Officer & Chief Product Officer, SOPHiA Genetics

Panelists:

**Thomas di Maio**, EU/Canada Diagnostic Lead, AstraZeneca**Elena Guerini Rocco**, Director of the Oncology Genetics Unit, Istituto Europeo di Oncologia

## Panels &amp; pitches

Presented by  CITELINE  
an rostellia company

16:30-17:15 Panel 7

Room Delhi, level 0

**What's next in R&D, innovation, and clinical development?**

AI and emerging clinical trends are reshaping the R&D landscape at unprecedented speed. This panel discussion will explore shifting scientific priorities, data-driven decision-making, and the evolution of trial design, offering clear perspective into how the next generation of therapies will be discovered, developed, and delivered.

Moderation: **Daniel Chancellor**, VP of Thought Leadership, Norstell

Panelists:

**Martin Svorc**, Director, Neurology & Immunology, Business Development & AI Strategy and Enablement Lead, Merck**Benjamin August**, Senior Director, Search & Evaluation – Research & Technologies, Daiichi Sankyo**Samir Ounzain**, CEO and Co-Founder, Haya Therapeutics**Michael Pitzner**, Group General Counsel, Senior Vice President Legal and Business Development, Molecular PartnersPresented by  zühlke  
empowering ideas

17:30-18:15 Panel 10

Room Delhi, level 0

**AI-powered pharma R&D, end-to-end: Connecting data, labs, and decision**

AI is embedded across pharma R&D, yet many programmes still stall at pilot stage. For life sciences leaders, the question is no longer whether to use AI, but how to turn it into sustained impact. Real progress depends on connecting how data is generated, shared, and reused across the value chain. This panel explores how to link labs, data, and decisions at scale – from autonomous labs to clinical and real-world evidence – and shares candid lessons on what works, where friction remains, and what must change to deliver measurable business value.

Moderation: **Thibault Geoui**, Thought Leader in Data & AI for the Pharma & Biotech Industry, Zühlke

Panelists:

**Ashiq H. Khan**, Chief Business Officer, Evotec**Constantin Landers**, Life Sciences Lead D-A-CH, Nvidia**Gerit Brandenburg**, Senior Director of AI and Automation in Drug Discovery, Merck**Le (Muller) Mu**, MLOps lead, Computational Sciences Center of Excellence, Roche

## Panels & pitches

Presented by



14:30-15:15 Panel 1

Room Kairo, level 0

### Optimizing digital endpoint strategies for success

Selecting the right clinical trial endpoints is essential for achieving study scientific objectives, regulatory success, investor confidence and efficient trial execution. This panel discussion will explore best practices for determining the optimal strategy to meet these goals, while balancing feasibility and cost. Attendees will also gain insight to selecting and overseeing a CRO partner effectively. Comprised of senior management from a CRO, biotech company, and an endpoint solutions vendor, the panel will provide diverse perspectives. Audience participation and Q&A will be encouraged.

Moderation: **Todd Rudo**, EVP, Chief Medical Officer, CLARIO

Panelists:

**Florian Vogl**, Chief Medical Officer

**Lewis Cameron**, CEO, Evestia Clinical CRO

**John Ohrn**, SVP, Global Partnerships, CLARIO

**Chris Clendening**, SVP Biotech Operations and Product Management, CLARIO

Presented by



15:30-16:15 Panel 4b

Room Kairo, level 0

### Engineering success: How partnerships transform early biotech into fundable ventures

In today's increasingly complex and capital-intensive biotech landscape, early-stage companies face mounting pressure to demonstrate not only scientific innovation, but also a clear path to scalability, manufacturability, and commercial success. Strategic partnerships are emerging as a critical lever to bridge this gap—transforming promising science into investable opportunities.

This panel will explore how collaborations between biotech startups, CDMOs, and venture capital stakeholders can effectively de-risk early-stage innovation.

Moderation: **Zara Asgharpour**, Director External Innovation Integrated Biologics R&D, Lonza

Panelists:

**Peter Droc**, Head of Licensing, Lonza

**Tristan Beppler**, CEO, Open Protein AI

**Klaus Orlinger**, CSO, Valanx Biotech

**Nikita Sharma**, Principal, Ridgeline - a Versant incubator

## Panels & pitches

Presented by 

16:30-17:15 Panel 8

Room Kairo, level 0

### Your pipeline isn't the bottleneck - your organization is: Learning velocity as the hidden value driver in Swiss biotech

In today's biotech landscape, capital is scarce and pipelines are strong – yet many companies struggle to deliver. The difference increasingly lies in organizational tenacity: the ability to adapt, reskill and execute under continuous pressure. This panel challenges where true bottlenecks sit and explores how learning velocity determines which companies turn funding into sustainable value.

Moderation: **Eva Perez Casesmeiro**, Head DDIT US&I Marketing & Customer Engagement, Novartis

Panelists:

**Sarah Holmes-Klotz**, CHRO, Santhera

**Melanie Rolli**, Former Group CEO, Boardmember & Advisor, Helsinn

**Alan Rankin**, CPO, Moderna

**Annett Zippel**, Partner & People Advisor, KennedyFitch

Presented by




17:30-18:15 Panel 11

Room Kairo, level 0

### Beyond the database: Turning clinical trial data into strategic advantage

Clinical trial data is more than a regulatory deliverable — it is a long-term strategic asset. This panel explores how early- and mid-stage biotech companies can move beyond database lock and build data infrastructures that enable scientific insight, cross-trial integration, and commercial leverage. Learn how structured data governance strengthens decision-making, accelerates partnerships, and directly impacts company valuation in competitive markets.

Moderation: **Cornelia Baumgartner**, Owner and Founder, Cetacea Clinical

Panelists:

**Ulf Grawunder**, CEO, T-CURX

**Elisabeth Steiger**, Senior Director Clinical Data Management, Metronomia

**Royden James**, Chief Product Officer, Viedoc

**Günter Fingerle-Rowson**, Chief Medical Officer, Tubulis

## Panels & pitches

Presented by **Deloitte.**

14:30-15:15 Panel 2

Room Shanghai 1+2, level 0

### Engineering longevity: Where science, innovation and the future of health systems converge

Health and longevity are emerging as one of defining frontiers of health of the next decade. As populations age and chronic disease burdens rise, innovations in science and technology are reshaping how we understand – and potentially intervene in the biological processes that drive ageing. Breakthroughs in aging biology, AI-driven diagnostics, and preventive medicine are opening the door to interventions that could extend not just lifespan, but healthspan. How can pharmaceutical innovation, strategic capital, nutritional science, and technology platforms work together to translate advances in longevity science into scalable and sustainable health?

Moderation: **Andrea Feigl**, Senior Director, Health Financing Strategy, Deloitte

Panelists:

**Alexandra Vallon-Eberhard**, Senior Director, Global Strategy & Partnering, Roche

**Anne Marije van Harten**, Investment Director, Apollo Health Ventures

**Ricardo Gaminha Pacheco**, Head of Strategic Partnerships, Insilico Medicine

Presented by **TIBIO**

15:30-16:15 Panel 5

Room Shanghai 1+2, level 0

### Bioremediation and beyond: Biotechnology for resilient soils and sustainable living

Soils face growing pressure from contamination and land use changes, yet biotechnology offers tools for their recovery. This panel unites experts from agrochemistry, biotech industry, and public sector to explore how environmental biotechnology and cleantech work in real-world contexts. Topics include biological remediation, innovation at the science-industry interface, and pathways toward sustainable soil management. The discussion addresses current limitations and future directions, connecting applied expertise with scientific perspectives to show how biotech drives environmental change.

Moderation: **Rita Di Martino**, Head of Biology, TIBIO

Panelists:

**Anne-Laure Gassner**, Scientific Project Leader, Federal Department of Defense, Civil Protection and Sport

**Federica Torrigino**, Research Engineer, Casale

**Michal Brylinski**, Founder & CEO, Bionrec

**Guillaume Boisard**, Project Manager, TIBIO

## Panels & pitches

Presented by **IQVIA** **PHARMA BIOME**

16:30-17:15 Panel 9

Room Shanghai 1+2, level 0

### From data to discovery: Shaping the future of microbiome therapeutics

Join us for a dynamic session featuring a panel discussion on the recent developments in the microbiome field. Experts, investors, and biotech leaders will explore key achievements, challenges, and success factors in microbiome-based therapies and especially how data are shaping the future of the field.

Moderation: **Tomas de Wouters**, CEO, PharmaBiome

Panelists:

**Alan Harris**, Senior VP Global R&D, Ferring Pharmaceuticals

**Benjamin Hadida**, CEO, Exeliom Biosciences

**Mat Robinson**, Senior VP Research, Microbiotica

**Aurelio Arias**, Director, IQVIA

Presented by **COHESION BUREAU**

17:30-18:15 Panel 12

Room Shanghai 1+2, level 0

### The art of the deal: Why some biotechs get it and others don't

The panel "The art of the deal: Why some biotechs get it and others don't" will examine how biotech fundraising and partnering decisions are actually made, looking at how subjects such as data quality, team credibility, market timing, and risk tolerance influence capital allocation from the perspectives of CEOs, VCs, potential partners and media.

Moderation: **Richard Jarvis**, Partner, Cohesion Bureau

Panelists:

**Gabor Gyölvérsi**, Principal, Novo Seeds

**Cormac Sheridan**, Senior biotech reporter

**Karen Wagner**, Managing Partner, Ysios

## Panels & pitches

Presented by



14:30-15:15 Panel 3

Room Shanghai 3+4, , level 0

### Beyond transactions: Building sustainable Swiss-China partnerships

As the biotechnology world embraces multipolarity, new bridges need to be built between countries to create value. China and Switzerland are two heavyweights in the global life sciences ecosystem. How could Swiss and Chinese companies use the strengths of each other to drive innovation and to establish a sustainable and mutually beneficial partnership model? Join our discussion with experienced cross-border biopharma bridge makers.

Moderation: **Peter Mozerov**, Senior Manager, KPMG

Panelists:

**Kuno Gschwend**, Deputy Head, Swiss Business Hub China, Embassy of Switzerland in China

**Bettina Ernst**, CEO, Bernina Bioinvest

**Eric Adam**, Chief Operating Officer, Haya Therapeutics

**Henri de Vlam**, Senior Business Development Manager, Chime Biologics

**Peter Zeng**, Managing Director, Zeyu Capital

Presented by



15:30-16:15 Panel 6

Room Shanghai 3+4, , level 0

### The merits and challenges of Swiss-Japanese partnerships

This panel explores partnerships between Swiss biotech companies and Japanese pharmaceutical firms, focusing on key advantages, challenges, and cultural alignment. It will also examine alternatives to equity financing and share practical insights into structuring and sustaining successful cross-border collaborations.

Moderation: name can be found on our website

Panelists:

**Dragan Grabulowski**, CEO, Araris

**Barbara Angehrn**, CEO, Numab

**Marc Gitzinger**, CEO, BioVersys

## Panels & pitches

Presented by



16:30-18:15 Pitch

Room Shanghai 3+4, level 0

### Future stars

Showcases a curated group of high-quality Swiss biotech companies developing innovative solutions across therapeutics, diagnostics, and enabling technologies. Each company will present its vision, science, and value proposition, followed by a live Q&A. The session offers investors, partners, and industry leaders early insight into the next wave of Swiss biotech innovation.

Moderation: **David Urech**, Vice President, Swiss Biotech Association  
**Bettina Ernst**, Vice President, Swiss Biotech Association

Jury: **Luca Bolliger**  
**Markus Goebel**  
**Patrick Burgermeister**

Pitching companies:

<b>16:38</b>	Allegria Therapeutics	<b>17:26</b>	Interax
<b>16:46</b>	Aukera Therapeutics	<b>17:34</b>	MetaLead
<b>16:54</b>	ClearideBio Therapeutics	<b>17:42</b>	MyoPax
<b>17:02</b>	Immitra Bio	<b>17:50</b>	Nerai Bioscience
<b>17:10</b>	InkoCell	<b>17:58</b>	Phialogics
<b>17:18</b>	InkVivo Technologies	<b>18:06</b>	Seito Biologics

Find details about the panel discussions here... →










... and about the pitching sessions here →



## Emerging biotech companies

Presented by **PUREOS**  
BIOVENTURES

Time	Company	Room Singapore, level 2
14:30	Pureos Bioventures	
14:45	OphthaNova	
15:00	SwitchKine	
15:15	HemastaTx	
15:30	EvlaBio	
15:45	Humion	
16:00	Ultimate Medicine	

Moderation: **Dominik Escher**, Managing Partner, Pureos Bioventures  
**Anne Grahl**, Investment Manager, Pureos Bioventures



Find details about the presenting companies here →

Presented by 

### 16:45-17:30 Pitch Room Singapore, level 2

#### Nucleate Switzerland: Showcasing the future of life sciences

Nucleate Switzerland will host a dedicated pitch session featuring selected Activator teams, showcasing some of the most promising early-stage, science-driven startups emerging from academia. These teams will present their innovations to an international audience of investors, pharma leaders, and biotech experts, creating exciting opportunities for connection, collaboration, and future growth.

Nucleate brings a highly curated pipeline of science-driven startups alongside a globally recognized network. As a global nonprofit with centralized leadership and active chapters across Europe and the US, we connect emerging innovators with investors, industry leaders, and partners worldwide.

Moderation: **Ebru Topcu Barileva**, Co-Managing Director, Nucleate Switzerland

Jury: **Sarah Holland**, CBO, CDR Life & President, Swiss Healthcare Licensing Group  
**Anne Marije van Harten**, Investment Director, Apollo Health Ventures

Pitching companies:

16:50	MutaDent	17:10	Versarys Bioscience
17:00	Talixeon Therapeutics	17:20	ZuriEV

Presented by 

### 17:45-18:30 Pitch Room Singapore, level 2

#### Meet the Venture Leaders Biotech 2026

Meet the 2026 Swiss National Startup Team in Biotech before they embark on their exclusive roadshow to Boston!

Join us for an exciting evening as 10 of Switzerland's most promising biotech startups take the stage to pitch their breakthrough innovations. This is a unique opportunity to discover the companies shaping the future of biotech and connect with founders, investors, and ecosystem leaders.

The Venture Leaders Biotech program is organized by Venturelab and supported by the University of Basel, EPF Lausanne, ETH Zurich, Hansjörg Wyss, Kellerhals Carrard, and VISCHER.

Moderation: **Jordi Montserrat**, Co-Founder and Managing Partner, Venturelab  
**Maurice Stäheli**, Project Manager, Venturelab

Pitching companies:

17:45	Baio Labs	18:10	Immitra Bio
17:50	Baxiva	18:15	NanoZymeX
17:55	Biodelphis Tx	18:20	Translation-X
18:00	Bioscibex	18:25	UNOMR
18:05	GlioCART	18:30	Visienco

## Clinical stage companies

Presented by



Time	Company	Room Montreal, level 2
14:30	Celonic	
14:45	Topadur Pharma	
15:00	Oculus Operations	
15:15	Azafaros	
15:30	Genevant Sciences	
15:45	Light Chain Biosciences	
16:00	CanVirex	
16:15	EsoCap	
16:30	Break	
16:45	Basilea	
17:00	OM Pharma	
17:15	NovaGo Therapeutics	
17:30	AB2 Bio	
17:45	MetrioPharm	
18:00	Vaderis Therapeutics	

Moderation: **Georg Blaser**, VP of Biologics Development Center, Celonic Group

## Commercial stage companies

Presented by **Lonza**

Time	Company	Room Sydney, level 2
14:30	Lonza	
14:45	Revvity	
15:00	Labcorp Holdings	
15:15	Parexel International	
15:30	PolyPeptide Group	
15:45	Oncodesign Services	
16:00	Cube Biotech	
16:15	Sartorius Stedim	
16:30	Break	
16:45	Vetter Pharma	
17:00	Santhera Pharmaceuticals	
17:15	Thermo Fisher Scientific	
17:30	KBI Biopharma	
17:45	INITS SMO	
18:00	Alphalyse	

Moderation: **Cristina Grigore**, Director Commercial Development, Integrated Biologics, Lonza

## Moderated networking tables

Presented by  ADIMAB

14:30-15:00 Networking table 1

Room Rio, level 2

### Challenges and solutions in discovery, generation, and characterization of multispecifics

There is an increasing understanding that monospecific antibodies are often insufficiently effective across all patients and/or indications. This has led to a growing interest in bispecific and multispecific modalities to target multiple signaling pathways and/or cell types. The goal of this roundtable will be to describe the current challenges in the discovery, generation, and characterization of bispecific and multispecific antibodies. We will furthermore discuss if the field is approaching any consensus on preferred formats and geometries, and how to arrive at the best molecule for a given application.

Moderation: **William Roach**, Senior Director of Technology Alliances, Adimab

Presented by  CLINIGEN

15:10-15:40 Networking table 2

Room Rio, level 2

### Scaling from early research to clinical trials: What surprised you most?

An open conversation about the unexpected challenges biotechs encounter when moving from early research toward first-in-human and early-phase clinical development. Participants are invited to share real experiences – from CMC and manufacturing readiness to clinical supply timing, team coordination, and regulatory expectations – and explore how operational preparedness influences timelines and overall trial success.

Moderation: **Michelle Jung-Maltese**, Clinigen

## Moderated networking tables

Presented by  impag

15:50-16:20 Networking table 3

Room Rio, level 2

### The right raw material at the right time: How specialized distributors shape the quality and speed of biotech innovation

The reliable sourcing and handling of chemical raw materials is one of the most underestimated factors in biotech innovation. This roundtable explores the strategic role specialized distributors play – from supply chain resilience, local warehousing and customs management, to formulation expertise, regulatory compliance and industrial-scale volume supply. With 100 years of distribution experience, deep supplier relationships and institutional knowledge, specialized distributors are more than middlemen – they are critical partners in bringing biotech innovation to life.

Moderation: **Markus Sierigk**, Head of Pharma, IMPAG

Presented by  Sciensus  
Fastest route to patients in Europe

17:10-17:40 Networking table 4

Room Rio, level 2

### From molecule to companion: Building digital patient support in a regulated world

Sciensus will host a practical session exploring how digital patient support can become a scalable source of commercial value for biotech, improving adherence, generating real-world evidence and strengthening launch and lifecycle strategy.

Moderation: **Katie Duncalf**, Director Of Innovation & Market Strategy, Sciensus  
**Lucia Rüdlinger**, Head of Regulatory Affairs, VIPS Representative Swiss Pharma Association

Find details about the networking tables here →



## Global Village

Room San Francisco, level 3

### Welcome to the Global Village at the Swiss Biotech Day 2026 - The power of international collaboration

The Global Village, spearheaded by the **Swiss Biotech Association**, serves as a premier platform to foster international collaboration and networking within the biotech and life sciences industries. In partnership with leading Swiss organizations, it offers a continuous, year-round gateway for global biotech clusters to forge and deepen strategic, long-term partnerships within Switzerland's thriving biotech ecosystem.

The **Global Village mission** is centered around:

- **Connecting global life sciences hubs with Swiss biotech leaders**  
Leverage the **international reception (p. 29)** and **marketplace (p. 29)** to meet and connect with international delegations, or visit them directly at their booths in the **Global Village exhibition area (p. 25)**.
- **Empowering international delegations**  
Take part in the **bilateral roundtable discussions (p. 30)**, designed for international delegations seeking to build and strengthen long-term, sustainable business relationships and collaborations with key decision-makers in the Swiss biotech ecosystem.
- **Driving collaborative excellence**  
Join the **Global Village stream (p. 32)**, including the **Global Village plenary session**, where we highlight the power of international collaboration, encourage the exchange of best practices, and foster joint initiatives that create mutual value for all stakeholders.

Since its inception in 2022, the Global Village has welcomed delegations from **all five continents**, underscoring its success in advancing global biotech collaboration.

This year, the Global Village is hosting a record number of **31 delegations**, and all Swiss Biotech Day participants are welcome to attend and actively contribute to the program.

**Find further information about the Global Village here →**



## Delegation

### Africa – booth GV21b

#### Participating companies:

Africa Collective, Biomine Health, Cape Bio, CSIR - Council for Scientific and Industrial Research, CureRoot, Department of Science, Technology and Innovation, Inqaba Biotec, Liqid Medical, OneBio, Ortho Design, Stellenbosch University, Technology Innovation Agency, TokaBio



### Australia – booth GV17

#### Participating companies:

360biolabs, Accelagen, Avion CRO, Bentleys, CMAX Clinical Research, CPL, Crux Biolabs, Linear Clinical Research, Nucleus Network, Pharmsky Research (Australia)



### Baden-Württemberg – booth GV7

#### Participating companies:

Baden-Württemberg International, BioRN Network, Bimovis



### Bavaria – booth GV8

#### Participating companies:

Bayern International, Invest in Bavaria, BioM, BSL Bioservice Scientific, Ethris, Fördergesellschaft IZB, Fraunhofer ITEM, Granzer Regulatory Consulting & Services, IMP, Labor LS, Laboratories Munich, leon-nanodrugs, Project Pharmaceuticals, Spark Microgravity, Staburo, TQ Therapeutics, Trophic Communications



### Canada – booth GV14

#### Participating companies:

20/20 OptimEyes Technologies, 3DBiofibr, Access Innovation BioBridge, Atlantic BioCorp, BioAro, BioBox, Blue Ocean Technologies, CCRM, Copoly.ai, Cura Therapeutics, Diex Recherche, Eyam Health, Genaiz, InTheKnow PharmaSolutions, KreaMedica, Modulari-T, Molecular Forecaster, Ness Therapeutics, Pegasus Biotech Incorporated, PRIME – Next Generation Precision Medicine, Royalmount BioPharma Services, Sciences Cinq Prime/Five Prime Sciences, Scotiaderm, Sussex Research Laboratories, Trade Commissioner Service / Government of Canada, Voxcell Bioinnovation



### Chile – booth GV6c

#### Participating companies:

CBT Sofofa Hub, Codebreaker, Embassy of Chile in Switzerland, Farmoquímica del Pacifico, Luyef Biotechnologies, Pewman Innovation, Phage Lab, ProChile. Synergia Bio



## Delegation

### China – booth GV20

#### Participating companies:

ABclonal Technology, Biocytogen, Canton Biologics, LTZ Therapeutics, Medicilon, Porton Pharma Solutions, SBH China, Sphinx Scientific Laboratory (Tianjin), XtalPi



### Emilia Romagna – booth GV25b

#### Participating companies:

Camera di Commercio Italiana per la Svizzera, Focalis, Promos, TPM



### Estonia – booth GV21c

#### Participating companies:

Chemestmed, Enterprise Estonia, Estonian Embassy, Helmes, Metrosert Applied Research Center, Ministry of Foreign Affairs of Estonia, Selfdiagnostics, Tartu Biotechnology Park, TBD Pharmatech, vectiopep



### Flanders – booth GV6b

#### Participating companies:



### France – booth GV26

#### Participating companies:

Accueil - Apmonia therapeutics, Bioseb, Cell Environment, Cilcare, ICTA, Kimialys, LFB, PLL Therapeutics, Research Pieces, Servier



### Greece – booth GV6a

#### Participating companies:

ABCureD, Critica Pharma, Nudge Care, Oncolipsy, Pharmassist, PKNM Solutions, Prinsus



### Hong Kong – booth GV13

#### Participating companies:

Hong Kong-Shenzhen Innovation and Technology Park, InvestHK, OncoNex-Remunity, Quant Biomarkers, SunRegen Healthcare AG



### India – booth GV10

#### Participating companies:

Aganitha AI, Aragen Bio, Ascelis Peptides, Clinixel, Cognizant, Neuland Laboratories, Nucelion Therapeutics, Pi Health Sciences, Sai Life, Zasya Life Sciences



## Delegation

### Italy – booth GV29b

#### Participating companies:


PerfeTTO network



### Japan – booth GV19

#### Participating companies:

Asahi Kasei Pharma, Astellas, Daiichi Sankyo Europe, DeSC Healthcare, Eisai, iBody, Itochu Europe, Kissei Pharmaceutical, Maruho, Matrixome, NTT Data, Sekisui Chemical, Swiss Business Hub Japan, Tillotts Pharma, Veritas In Silico, Yokogawa



### Latvia – booth GV24

#### Participating companies:

AI Invest Labs, Biosan, Capture Study, Cellbox Labs, Double Helix Technologies, Inpharmatis, Institute of Solid State Physics, Latvian Institute of Organic Synthesis, Latvian Office for Innovation and Technology, Lexu Care, Longgenesis, PrintyMed, University of Latvia



### Lithuania – booth GV27

#### Participating companies:

Bious Labs, Expermentika, Fitodenta, LithuaniaBIO, Luko Laboratorija, Seqvision, VUGENE



### Netherlands – booth GV18

#### Participating companies:

Dutch Embassy, Health Holland, iPsomics, RVO, Single Cell Discoveries, UMCG



### Nordic Countries – booth GV16

#### Participating companies:

Acapo Onsagers, APNC, Atrogi, Aurlide, Berking Theranostics, Business Finland, Capsih, Celectricon, ChainPeptides, Curacell, Evogence Biologics, Genomill, Innosiamo, Invest in Skåne, Kinsea Lead Discovery, Life Science Nord, Mo:re, ModelMole, Medicon Valley Alliance, Neurometa, NorthX Biologics, Paras Biopharmaceuticals, SPARK Norway | UiO:Life Science, Sweden Bio, The Life Science Cluster, Vactech



### North Carolina – booth GV23

#### Participating companies:

Aesara, Economic Development Partnership of North Carolina, iOrganbio, Jericho Sciences, Kymanox, Moon Pharma, Tanner Pharma Group, Teguar



## Delegation

### North Rhine-Westphalia – booth GV25a



#### Participating companies:

BIO Clustermanagement NRW, BIO.NRW, Cellbox Solutions, Khanu, Lead Discovery Center, NRW.Global Business, Taros Chemicals

### Oregon – booth GV11



#### Participating companies:

Araceli Biosciences, Business Oregon, Caravel Bio, Genentech, Oregon Health Sciences University, Oregon Life Sciences, Oregon State University

### Portugal – booth GV21a



#### Participating companies:

Accelbio, AICEP, Genlbet Biopharmaceuticals - Recipharm, LXbio, Magmascience, Rodon Biologics, Universidade de Coimbra

### Saxony – booth GV5



#### Participating companies:

AI-Driven Therapeutics, biosaxony/leap:up, Diamics, futuresax, Katana Labs, MDTB Cells, Saxocell, Saxony Trade & Invest

### Slovenia – booth GV12



#### Participating companies:

Acies bio, Bio-ReCell, Brinox, Cleangrad, Herman & partnerji, Jafra, Labena, Lotric Metrology, Medis, Metronik, Naya Life Sciences, Priot, Zust-AI, Virella Science

### South Korea – booth GV9



#### Participating companies:

AIT Studio, Anpoly, Cellnit, EZcaretech, Fustlab, Graphene Square Chemical, Ilias Biologics, Jetema, Korea Trade-Investment Promotion Agency, L-Base, Medipost, Moss Bio, Onesoftdigm, Preclina, Radahaim, Rokit Healthcare, Selexcine, ST Pharm

### Spain – booth GV25c



#### Participating companies:

AseBio, BIOSPAIN

### Taiwan – booth GV28



#### Participating companies:

Development Center for Biotechnology, Excelsior Biopharma, GlintMED Innovation, Kri-San Biotech, Mycenax Biotech, Onward Therapeutics, Protect Animal Health, Taiwan Bio Industry Organization

## Delegation

### UK – booth GV15



#### Participating companies:

ApconiX, BIA, BioAscent, Biocatalysts, BioPartner UK, British Embassy – Department for Business and Trade, British Embassy – Science and Technology Network, Centrix Pharma Solutions, CGT Catapult, CPI, Evestia Clinical, Firefinch, iGii, Ingenza, Lucideon, Medecines Discovery Catapult, Northern Light Microscopy, Pharmora, Rouken-Bio, Scancell, Sciento Technology, Scott Partnership Holdings, Seda PDS

### Wallonia – booth GV22



#### Participating companies:

Approach Belgium, Ateliers Ferrari, Awex, Boostcode, Cenexi, Cer Groupe, Coris Bioconcept, ICTEAM institute, I cure Belgium, IDDI, Ipratech, Legiapark, MedReSyst, Oncoradiomics, Phoenix Biosciences, Qity, Sagitta Biotech, Salamander, Santero Therapeutics, Secoya Technologies, Seqalis, Syngulon, Telemedicine Technologies, The Clinical Pharmacology and Toxicology Research Unit, The Research Unit in Biology of Microorganisms, UCLouvain, Université libre de Bruxelles, White Raven

### May 4, 18:00-18:45

#### International reception

Room San Francisco, level 3

Join us for a dedicated networking reception at the Global Village, where participants can connect with the international delegations in a relaxed and engaging setting. The event will feature welcome remarks by Michael Altorfer, CEO of the Swiss Biotech Association, and speeches from our long-standing Global Village partners: Switzerland Global Enterprise (S-GE) and Innosuisse.

The opening of the international reception will feature a performance on the alphorn, blending traditional sound with a modern interpretation.

### May 5, 15:30-16:30

#### Marketplace reception

Room San Francisco, level 3

The Marketplace is the closing networking event of the Global Village, where international delegations will share drinks and snacks from their home countries—celebrating cultural diversity and global collaboration. Delegates will be invited to share their key achievements at Swiss Biotech Day and offer an outlook on future opportunities. The event will conclude with farewell speeches by Michael Altorfer, CEO, and Patrick Amstutz, President of the Board at the Swiss Biotech Association, including the announcement of this edition's country partnership of the year.

## Bilateral roundtable discussions

Please join us for roundtable discussions, aiming to facilitate partnerships and connect international representatives with the Swiss biotech industry for research, corporate collaborations, policy-making and investments.

Day 1		San Francisco (stage)
14:00-14:30	<b>Roundtable 1 – UK</b> Engineering biology: Practical pathways for Swiss-UK cross-border collaboration	
14:45-15:15	<b>Roundtable 2 – Nordics</b> Trusted Insights: A peer dialogue on biotech investment strategy	
15:30-16:00	<b>Roundtable 3 – Taiwan</b> The Swiss-Taiwan biotech dialogue 2026: Driving cross-border partnerships in a shifting regulatory era	
16:15-16:45	<b>Roundtable 4 – Oregon</b> Connecting engineering and biology ecosystems – from research to manufacturing	
17:00-17:30	<b>Roundtable 5 – Estonia-Lithuania</b> Scaling successful collaboration models between Switzerland and the Baltics in life sciences	
Day 2		San Francisco (stage)
12:00-12:30	<b>Roundtable 6 – India</b> Bridging innovation and scale: Building India-Switzerland biopharma value chains	
12:45-13:15	<b>Roundtable 7 – Spain</b> Opportunities to strengthen the ties between Spanish startups and the Swiss ecosystem by leveraging Eureka instruments	
13:30-14:00	<b>Roundtable 8 – Netherlands</b> Innovating women's health: Connecting Dutch and Swiss ecosystems	
14:15-14:45	<b>Roundtable 9 – France</b> France - Switzerland: Transforming research into treatments faster	
15:00-15:30	<b>Roundtable 10 – China</b> From catch-up to global partner: The implications of China's biotech rise for Europe	

# SWISS BIOTECH DAY

May 4-5, 2026  
Congress Center Basel

## The power of international collaboration Join our Global Village



- Meet over 3,000 decision makers from about 50 countries
- Connect with the global biotech community, CEOs and investors
- Explore and initiate collaboration with Swiss biotech leaders
- Drive cross-border investments
- Build public/private partnerships
- Enhance academic and translational cooperation
- Share best practices and influence policy development
- Promote talent exchange

The Global Village offers a continuous, year-round gateway for global biotech clusters to forge and deepen strategic, long-term partnerships within Switzerland's thriving biotech ecosystem.

If you are interested to participate in the Global Village find more info at [swissbiotech.org/global-village](https://swissbiotech.org/global-village) and contact us at [globalvillage@swissbiotech.org](mailto:globalvillage@swissbiotech.org).

Presented by:



Supported by:



## Global Village track

Presented by  eureka  
innovation beyond bordersSupported by    SWISS  
BIOTECH  
Global Village

## 14:15-15:00 Plenary session

Room Osaka/Samarkand, level 3

**Eureka: Non-dilutive funding for global innovation collaboration – opportunities for biotech**

This plenary session will highlight Eureka, the world's largest public network for international R&D and innovation, spanning more than 45 countries. It will explore what makes non-dilutive funding programs effective for biotech and demonstrate how open, global collaboration models can broaden access to funding and accelerate innovation.

Moderation: **Andreas Gut**, Head of International Programs, Innosuisse

Panelists:

**João Curado**, CEO, Flomics Biotech**Bärbel Ulmer**, Director Business Development, InSphero**Brit Helle**, Director General, Eureka Secretariat**Laura Gunter**, President, North Carolina Life Sciences Organization**Lorenzo Leoni**, Founder and Managing Partner, Creadd VenturesPresented by  SWISS  
BIOTECH  
Global Village

## 15:15-16:00 Panel

Room Osaka/Samarkand, level 3

**Leveraging regulatory collaboration to strengthen public-private innovation partnerships**

The panel will examine how the Access Consortium can move beyond regulatory alignment to enable coordinated evidence generation, faster system adoption, and scaled innovation. It will highlight public-private partnerships that reduce duplication across regulatory, HTA, and real-world evidence pathways, improving predictability for market access.

Participants will explore cross-border RWE collaboration, stronger investor confidence, and positioning Access countries as a globally competitive innovation bloc. The session will also introduce Access Innovation BioBridge as a non-regulatory platform to drive these efforts and launch near-term pilot.

Moderation: **Jaspreet K. Grewal**, Managing Partner, Access Innovation BioBridge

Panelists:

**Jean-Paul Lemieux**, Canadian Ambassador to Switzerland and Liechtenstein**Zara Asgharpour**, Head of External Innovation, Lonza**Jörg Schläpfer**, Chief of Staff and Head Sector External Relations, Swissmedic

## Global Village track

Presented by  SWISS  
BIOTECH  
Global Village

## 16:15-17:15 Pitch

Room Osaka/Samarkand, level 3

**Global innovation showcase: Early-stage startups from the Global Village**

Explore discovery and early preclinical biotech startups from around the world, developing innovative products and technologies to address global health challenges. Join us to discover the future of biotech, hear from visionary founders, and uncover exciting investment opportunities.

Moderation: **Maximilien Murone**, Liaison Basel Northwestern Switzerland, Swiss Biotech AssociationInvestor jury: **Michael Hübner**, Director Early Innovation Partnering, Johnson & Johnson | **Frederic Levy**, Chief Scientific Officer and Head of External & Internal Innovation, Debiopharm | **Georg Wiebecke**, Board Member, BioValley Basel | **Lorenzo Leoni**, Founder and Managing Partner, Creadd Ventures | **Diego Braguglia**, Managing Partner, VI Partners | **Jana Obajdin**, Analyst, BioGeneration Ventures

<b>16:15</b> Introduction	<b>16:45</b> Berking Theranostics
<b>16:20</b> Phialogics	<b>16:50</b> Virella Science
<b>16:25</b> KinSea Lead Discovery	<b>16:55</b> Summa Biotech
<b>16:30</b> Cura Therapeutics	<b>17:00</b> Jericho Science
<b>16:35</b> Sagitta Biotech	<b>17:05</b> iBody
<b>16:40</b> Modulari-T Bioscience	<b>17:10</b> Voting and closing remarks

## Global Village track

Presented by **SWISS BIOTECH**  
Global Village

12:15-13:00 Panel

Room Osaka/Samarkand, level 3

### Strengthening Europe's biotech competitiveness through collaboration across the life science ecosystems

As Europe develops new policy instruments such as the upcoming EU Biotech Act, strengthening the competitiveness of its life science sector requires closer collaboration across the entire ecosystem – from established pharma and biotech hubs to emerging innovation regions. This panel will explore how different parts of Europe's life science landscape contribute to innovation capacity through talent, data, research and industrial capabilities. The discussion will focus on how stronger cross-regional and cross-sector collaboration can enhance Europe's global position in biotechnology.

Moderation: **Agne Vaitkeviciene**, Vice President, LithuaniaBIO

Panelists:

**Sujoy Chowdhury**, Senior Director Clinical Innovation & Operational Excellence (International Operations), Novo Nordisk

**Ernst Nagel**, Operations Director, Health Holland

**Delphine Costa**, CEO, The Life Science Cluster

Presented by **SWISS BIOTECH**  
Global Village

13:15-14:15 Pitch

Room Osaka/Samarkand, level 3

### Global innovation showcase: Late-stage startups from the Global Village

Explore late preclinical and clinical biotech startups from around the world, developing innovative products and technologies to address global health challenges. Join us to discover the future of biotech, hear from visionary founders, and uncover exciting investment opportunities.

Moderation: **Maximilien Murone**, Liaison Basel Northwestern Switzerland, Swiss Biotech Association

Investor jury: **Michael Hübner**, Director Early Innovation Partnering, Johnson & Johnson | **Kostas D. Kaloulis**, Venture Partner, ND Capital | **Jana Obajdin**, Analyst, BioGeneration Ventures | **Diego Braguglia**, Managing Partner, VI Partners

**13:15** Introduction **13:45** TetraKit Technologies

**13:20** PLL Therapeutics **13:50** Atrogi

**13:25** CuraCell **13:50** Selexcine

**13:30** Ethris **13:55** Vactech

**13:35** MDTB Cells **14:00** Apmonia Therapeutics

**13:40** Isorea **14:05** Voting and closing remarks

## Global Village track

Presented by **SWISS BIOTECH**  
Global Village

14:30-15:15 Panel

Room Osaka/Samarkand, level 3

### Speed to clinic: Global perspectives on conducting clinical trials in Switzerland, Hong Kong, Australia and the MENA Region

Selecting the optimal location for early clinical trials can significantly influence the speed and success of biotech innovation. This panel will bring together key stakeholders from leading and emerging international ecosystems to discuss opportunities, regulatory pathways, and practical considerations for executing clinical trials across jurisdictions.

Moderation: **Simone Ferbitz-Scheurer**, Head of Clinical Trials Division, Swissmedic

Panelists:

**Stella Sun**, Principal Manager Life & Health Sciences, InvestHK

**Eric Adam**, COO, HAYA Therapeutics

**Racha Fayad**, Life Sciences Strategy Team, KPMG

**Christel Gremion Viatte**, Director Global Regulatory CTA, CSL

**Shu Lam**, Chief Business Development Officer, CMAX Clinical Research

## Plenary session

### 10:00-12:00 Plenary session II

Room Montreal, level 2

Moderation: **Monika Jones**

#### 10:00 Opening remarks

**Michael Altorfer**, CEO, Swiss Biotech Association

#### 10:10 Keynote panel on Swiss biotech ecosystem

Host: **Patrick Amstutz**, President of the Swiss Biotech Association

Panelists:

**Alex Mayweg**, MD, Versant Ventures

**Luca Santarelli**, CEO, Windward Bio

**Mark Dawson**, Head, Roche Pharma Research and Early Development (pRED)

**Otello Stampacchia**, Founder Omega Ventures & Co-initiator of the European Life Science Coalition

#### 10:55 Swiss Biotech Report

**Frederik Schmachtenberg**, Partner, Global Life Sciences Lead for Financial Accounting Advisory Services, EY

#### 11:10 Swiss Biotech Success Stories Award

**Jürg Zürcher**, jury president

#### 11:25 Investor panel: Cross-Atlantic perspectives on Swiss biotech

Host: **Seth Lewis**, Executive Vice President Corporate Finance, Molecular Partners

Panelists:

**Andrew Hack**, Bain Capital

**Arjun Goyal**, Vianti Capital

**Naveed Siddiqi**, Novo Ventures

## Panels & pitches

Presented by  AESARA

### 09:00-09:45 Panel 13

Room Delhi, level 0

#### Betting on uncertainty: Navigating policy volatility in pharmaceutical investment and commercialization

Policy volatility and economic uncertainty are reshaping the pharmaceutical innovation landscape. From the Inflation Reduction Act in the USA, the EU pharma package, EU HTA legislation, and reshaped global reference pricing baskets following MFN actions from the US, investors and manufacturers alike are recalibrating their models for asset risk and reward. This panel brings together experts in finance, business development/licensing and commercialization to explore uncertainty – regulatory, political, and macroeconomic – impacts financing decisions for pipeline assets and go to market potential.

Moderation: **Jennifer Cain Birkmose**, Vice President Europe, Aesara

Panelists:

**Sezai Taskin**, CEO, ViferaXS

**Michael Schroeter**, Co-Head Sustainable Healthcare Equity, HSBC

**Alina Levchuk**, Head of Investor Relations, Nextech

Presented by  Swiss Biotech Association  satw technology for society

### 12:15-13:00 Pitch

Room Delhi, level 0

#### Showcasing the diversity of the Swiss industrial biotechnology

The industrial biotech pitching session will highlight the numerous industries in which biotech applications are used. It aims at presenting to the audience innovative companies active in foodtech, agritech and other fields, thereby highlighting the strength of this biotech segment.

Moderation: **Aditya Yellepeddi**, Head of industrial biotech chapter, Swiss Biotech Association

**12:15** Introduction

**12:20** SATW

**12:40** Bionomous

**12:25** Aleph Farms

**12:45** NeoCarbons

**12:30** The Cultured Hub

**12:50** ADM International

**12:35** Deasyl

**12:55** Closing remarks

## Panels & pitches

Presented by  BLANCLABO  
Laboratory equipment

13:00-13:45 Panel 19

Room Delhi, level 0

### Scaling up fermentation: How to pass the burn-rate phase and achieve profitability at low risk

In the race for a profitable business model, every penny of the cost of goods sold (COGS) counts. While single-use technologies offer a seemingly low barrier to entry, their hidden operational costs can become a death trap for start-ups targeting food commodity markets. This session challenges the conventional wisdom of “throwaway”. We will explore how new approaches in stainless steel fermenter making can drastically reduce the initial CAPEX while ensuring minimum operational costs. Join us as we break down the Total Cost of Ownership (TCO) and find out why steel, powered by Blanc-Labo, is the leanest choice for your bottom line.

Moderation: **Eric Laborde**, CEO, BLANC-LABO

Panelists:

**Klaus Kienle**, Co-Founder and Chief Production Officer, Food Brewer

**Pascal Torregrossa**, Head Global Operations Active Beauty, Givaudan

**Alexander Scheidel**, Head of Bioprocessing Solutions, Steinecker - Kronos

**Vivek Dogra**, Co-Founder and General Partner, DDF Fund

Presented by  Homburger  Hoffmann  
Partner

14:00-14:45 Panel 23

Room Delhi, level 0

### Practical use of AI tools in fundraising, partnering & finance

AI tools for fundraising, business development and finance are now widely available, but while large pharma companies are starting to deploy them at scale, most smaller biotechs have yet to embed them into their core business processes due to constraints around budget, risk and governance. The panel will examine how this gap is reshaping deal-making dynamics, what it means for both sides of the table, and how smaller companies can respond in a legally robust and practically actionable way, including a pointer to a forthcoming webinar series that will continue the discussion with deeper, hands-on insights.

Moderation: **Philipp Gutzwiller**, Managing Partner, CFS Advisors

Panelists:

**Luca Dal Molin**, Partner, Homburger

**Urs Breitenstein**, Partner, Hoffmann & Partner

**Avaleigh Milne**, Global Head of Business Development Strategy & Practice, Pharma Partnering, Roche

**Matti Kesti**, CSO, Floatz.ai

**Damian Kemper**, Developer, Werchota.ai

## Panels & pitches

Presented by  VERDEYA

15:00-15:45 Panel 27

Room Delhi, level 0

### Medicinal and industrial use of the hemp plant: Innovations in Switzerland

Hemp is one of humanity's oldest cultivated crops and a cornerstone of sustainable innovation. Traditionally valued for durable fibres, hemp is now gaining renewed attention as a source of non intoxicating cannabinoids such as cannabidiol (CBD). As scientific understanding and public acceptance grow, the industry faces new challenges in scaling from niche applications to global impact. This panel explores hemp's next development phase, highlighting innovation, regulatory evolution, and collaboration across medicine, wellness, food, and materials sectors.

Moderation: **Julia Hoeng**, VP Innovation & Product Development, Verdeya

Panelists:

**Gavin George**, Co-Founder and CEO, Purgene

**Gordon Dawson**, Director Product Development, Verdeya

**Jürg Gertsch**, Professor of Biochemistry and Pharmaceutical Biology, University of Bern

**Hans Daetwyler**, CEO, Swiss Plant Breeding Center

**Tonio Schwehr**, Applied Economist, EBP Schweiz

Presented by  Baker  
McKenzie.

16:00-16:45 Panel 31

Room Delhi, level 0

### Building resilient, value-creating transactions in an unpredictable environment

As regulatory frameworks tighten and global headwinds disrupt some elements of traditional collaboration models, biotech dealmaking is facing new challenges. This discussion highlights the tools, terms, and strategic approaches that companies are using to build resilient, value-creating transactions in an unpredictable environment.

Moderation: **Julia Schieber**, Partner, Baker McKenzie

Panelists:

**Oren Livne**, Partner, Baker McKenzie

**Antoine Khallouf**, Managing Director, Rothschild & Co Global Advisory

**Lev Kogon**, Vice President and Head of Business Development, Stealth Mode Biotech

## Panels & pitches

Presented by  PSI

09:00-09:45 Panel 14

Room Kairo, level 0

### Agentic AI in clinical trials: Where are we now, and where are we going to be?

PSI CRO will host a dynamic session on agentic AI in clinical trials, exploring its capabilities and potential. Sponsors, AI experts, and PSI CRO will discuss its role in tackling protocol complexity, improving efficiency, and meeting evolving regulatory demands. We will review current applications of agentic AI across protocol design, startup, enrollment, and data analysis, alongside future advances such as adaptive trials and semi-autonomous monitoring. A moderated debate will explore the real value of agentic AI, barriers to adoption, and what we expect to come next.

Moderation: **Kirill Soldatov**, Head Process Improvement, PSI CRO

Panelists:

**Florian Maurer**, Head of Clinical Development, Basilea Pharmaceutica

**Sezcan Ozturk**, Head of Europe & Vice President, Luzsana Biotechnology

**Daniel Morris**, Solutions Engineer, Arango

**Dmytro Baikov**, Vice President of AI, DataArt

Presented by  BIOMEDVC

12:15-13:00 Panel 17

Room Kairo, level 0

### Syndication in early-stage biotech: Chances and challenges

This panel explores early-stage biotech syndication between CVCs and seed investors. It covers roles, alignment, and evolving market dynamics, including selectivity and collaboration. Discussion highlights incentives, ticket sizes, and engagement, plus how strong syndicates are built and led. Panelists examine value inflection points, risk-sharing, and valuation trends. Differences between US and Europe are considered, alongside future funding roles. Challenges to syndicate financing rounds at early-stage will be discussed. Moderators will use prompts to deepen insight and reveal challenges, trade-offs, and practical lessons for founders.

Moderation: **Claudia Ulbrich**, Venture Partner, BiomedVC

Panelists:

**Valentin Piech**, Managing Partner, BiomedVC

**Jan-Philipp Kruse**, Senior Director, Lilly Ventures

**Roger Franklin**, Partner, Hadean Ventures

**Naveed Siddiqi**, Senior Partner, Novo Holdings

**Mathias Frederiksen**, Principal, Novartis Venture Fund

## Panels & pitches

Presented by  CSL

13:00-13:45 Panel 20

Room Kairo, level 0

### Designing the next generation of partnerships

This panel will explore how partnership structures are evolving across the biotech lifecycle. Using recent European examples, including VarmX and Memo Therapeutics, the discussion will examine how deal design is adapted to asset maturity, available data and execution requirements. Spanning early platform collaborations through to late-stage development agreements, the panel brings together biotech, investor and industry perspectives, and will also reflect on Europe's role in supporting cross-border collaboration and company building.

Moderation: **Rémi Droller**, Managing Partner, Kurma Partners

Panelists:

**Hervé Gisserot**, Executive Vice President, CSL

**Emmanuelle Lecomte-Brisset**, Senior Vice President, CSL

**Martijn Negen**, Chief Operating Officer, VarmX

**Lars Spenger**, Chief Financial Officer, Memo Therapeutics

Presented by  Schellenberg Wittmer

14:00-14:45 Panel 24

Room Kairo, level 0

### Life sciences ventures – exit strategies

When venture capital firms invest in private companies and publicly listed companies in sectors like pharmaceuticals, biotechnology, and medical devices, which questions need to be considered and addressed in advance to ensure successful exit transactions? Experts will discuss in a panel their experiences when establishing exit strategies.

Moderation: **Olivier Triebold**, Partner, Schellenberg Wittmer

Panelists:

**Maximilian Stör**, Head of Legal, Boehringer Ingelheim Venture Fund

**Robert Stein**, Partner, Gilde Healthcare

**Pascal Hubli**, Partner, Schellenberg Wittmer

## Panels & pitches

Presented by  XDC  
The Biologics Center

15:00-15:45 Panel 28

Room Kairo, level 0

### Beyond ADCs: The next wave of targeted bioconjugate therapeutics

Antibody drug conjugates (ADCs) transformed oncology, and bioconjugates are now expanding beyond ADCs. New modalities such as antibody oligonucleotide, peptide, degrader, and antibody fragment conjugates are enabling more precise targeting and new biology. This panel brings together pharma, biotech, venture, and CDMO leaders to discuss:

- Scientific breakthroughs driving new conjugate modalities
- Translating innovations into clinical development
- Manufacturing and quality challenges at scale
- Investment trends shaping the field
- The role of cross-industry collaboration in future innovation

Moderation: **Carl Deutsch**, CSO, NBE Therapeutics

Panelists:

**Jimmy Li**, CEO, WuXi XDC

**Sherry Gu**, CTO, WuXi Biologics

**Frederic Levy**, CSO, Debiopharm

**Zhizhong Joel Yao**, Partner, Sofinnova Partners

Presented by  Syneos  
Health

16:00-16:45 Panel 32

Room Kairo, level 0

### Beyond the data: Crafting the commercial story pharma partners believe in

In today's partnering environment, strong data alone no longer secures high value pharma deals. Successful assets are differentiated by the clarity and credibility of the commercial story behind them. This session brings together experienced dealmakers to explore how leading biotech teams translate clinical promise into narratives that resonate with potential pharma partners and investors. Through recent deal examples, the panel will examine how articulating the commercial story of the asset in a credible and realistic way, and how demonstrating execution understanding can accelerate trust and momentum, and shape deal success.

Moderation: **Marek Rombel**, Mng. Director Commercial Advisory Group, Syneos Health

Panelists:

**Martijn Negen**, Chief Operating Officer, VarmX

**Artal Moreno-Fortuny**, Exec. Director BD & Strategy, Alesta Therapeutics

**Marc Hennebert**, Managing Director Commercial Advisory Group, Syneos Health

## Panels & pitches

Presented by  OBELYSQ  
Quality Management System

09:00-09:45 Panel 15

Room Shanghai 1+2, level 0

### Implementation of a robust and pragmatic quality management system for biotechs

How to build your Quality Management System (QMS) without overcomplicating it, while meeting regulatory requirements?

This panel will explore how biotech companies can implement a QMS that is compliant, lean, fit-for-purpose, and sustainable – even with limited resources.

Bringing together experts who have navigated this journey from different perspectives, the discussion will focus on what truly matters: building a “right-sized” quality framework that meets regulatory expectations without unnecessary complexity.

Panelists will share real-world experiences on prioritizing and embedding quality into everyday operations.

Moderation: **Ludovic Moulin**, Managing Director, ObelysQ

Panelists:

**Bettina Buddis**, Head of Clinical Manufacturing, CDR-Life

**Claudia Escher**, Chief Operating Officer, Tolremo

**Jan Krikava**, Managing Director & Product Manager, Docuply

**Arnaud Levain Chavanon**, Managing Director, ObelysQ

Presented by  SLAS  
Come Transform Research

12:15-13:00 Pitch

Room Shanghai 1+2, level 0

### The SLAS startup pitch showcase

Selected startups will take the stage for a fast-paced, one-hour pitch session spotlighting breakthrough life sciences and lab automation technologies and commercial potential.

Modeled after SLAS Innovation AveNEW, our startup program evaluates compelling science, market opportunity and impact, and management team strength with an aim to connect innovators with industry users and investors. Prizes include a spot on SLAS Innovation AveNEW, plus awards from the city of Basel and Swiss Biotech Day.

Moderation: **Manuela Beil-Peter**, SLAS Europe Ambassador

Jury: **Olivier Frey**, Vice President Technology & Platforms, Insphero | **Samantha Paoletti**, Head Research and Business Development Life Science Technologies, CSEM | **Thomas Frech**, Lab Innovation Coach & Leader | **Kevin Keim**, Director Operations and Project Management, Walter Klybeck

**12:20** Asemblis **12:40** Magnostics

**12:30** AxCellerate **12:50** Prevision Medicine

## Panels & pitches

Presented by   Swiss Biotech Association

13:00-13:45 Panel 21

Room Shanghai 1+2, level 0

### From force to function: Empowering the next level of mechano-biology research

Cells and tissues are not only defined by their molecular composition but also by their mechanical properties, key drivers of function, disease progression, and therapeutic response. This panel brings together leading academic and industry experts to explore how advances in accessible, automated AFM technologies are opening mechanobiology to a much broader range of researchers.

Moderator and panelists can be found on our website

Presented by 

14:00-14:45 Panel 25

Room Shanghai 1+2, level 0

### Operational maturity in CMC – accelerating development from strategy to execution

Most CMC (Chemistry, Manufacturing & Control) delays are predictable, yet they keep happening, because strategy and execution operate in silos.

This panel brings together leaders from biotech, pharma, and CDMOs to discuss how organizations build CMC readiness, align technical and business decisions, and close execution gaps that consume time and value. Perspectives across the development value chain, from early-stage decisions to commercial scale.

Moderation: **Sonja Merkas**, Founder and CEO, Livinovea

Panelists:

**Christoph Becker**, CEO, Inofea

**Eduard Ayuso**, CTO, Dinamiqs

**Ivan Pogorelic**, Head of CMC, Nxera Pharma

**Jeffrey Grunkemeyer**, Associate Director Advanced Synthesis, Lonza

## Panels & pitches

Presented by 

15:00-15:45 Panel 29

Room Shanghai 1+2, level 0

### Challenges and pitfalls in selecting and developing cell-based bioassays

Cell-based bioassays are a cornerstone of potency testing, safety assessment, and regulatory approval, as they provide data that more accurately reflects cellular behavior than assays targeting isolated components. However, their development is highly challenging due to biological variability, complex mechanisms of action, and evolving regulatory expectations, making CBBAs a high-stakes element of drug development. This panel will cover:

- Method selection for different modalities, with a focus on potency
- Key considerations and common pitfalls in assay development
- Examples of potency assays for mAbs, ADCs, and other biologics

Moderation: **Charlie Brault**, Digital Marketing Manager, Solvias

Panelists:

**Daniel Galbraith**, Chief Scientific Officer, Solvias

**Thomas Millward**, Director Bioanalytics, Novartis

**Reginald Clayton**, Director Field Development, Head of Biosafety, Solvias

**Devadarssen Murdamoothoo**, Director of Operations Cell-based Bioassay, Solvias

Presented by 

16:00-16:45 Panel 33

Room Shanghai 1+2, level 0

### Biosimilar development and commercialization: Challenges and opportunities

Biosimilars are reshaping healthcare; expanding access, challenging established markets, and creating new pathways for growth. But beyond science and strategy lies a bigger question: How do we turn opportunity into lasting impact? This panel brings together leaders from across the ecosystem to share perspectives on the evolving biosimilar landscape and what it takes to thrive within it. The discussion explores ambition and responsibility, highlighting the importance of collaboration, strategic execution, and sustainable value creation in a rapidly changing global environment.

Moderation: **Luc-Alain Savoy**, Global Head of Pharma, SGS

Panelists:

**Haleh Hamedifar**, Chairperson, CinnaGen

**Benjamin Muller**, CEO, Biofidus

**Chris Lamb**, CEO, Sealantium Medical

**Eric Guenzi**, CEO, UGA Biopharma

## Panels & pitches

Presented by  CurieBio

09:00-09:45 Pitch

Room Shanghai 3+4, level 0

### Reverse pitch: What top biotech VCs are looking for

In this unique session, leading biotech VCs pitch their investment models to founders. Learn how each firm thinks about scientific risk, team, and path to clinic – and what sets them apart. A must-attend for anyone looking to raise capital or understand today's biotech venture landscape.

Moderation: **Katharina Kreymbourg**, CurieBio

Jury: members can be found on our website

09:00 Introduction

09:09 CurieBio

09:27 Ysios

09:18 Wellington Partners

09:36 Closing remarks

Presented by  Swiss Biotech Association

12:15-13:00 Panel 18

Room Shanghai 3+4, level 0

### Beyond equity: Navigating non-dilutive financing for growth

Equity is not the only path to fund innovation. This panel explores how biotech companies – from early stage to listed – can unlock capital through non-dilutive strategies. Our expert panelists from Switzerland and the United States will delve into early pharma collaborations / R&D partnerships, state-sponsored funding options and location packages, the power of royalty monetization, and value-creating outlicensing or spin-off structures. The session will highlight practical deal structures, key Swiss law and tax aspects, and real-world lessons on how to finance growth while preserving equity and strategic flexibility.

Moderation: **Daniel Häusermann**, Partner, Homburger

Panelists:

**Fabian Meier**, Partner, EY

**Hannah England**, Partner, Ropes & Gray

**Vincent Reardon**, Partner, Vischer

**Maurus Winzap**, Partner, Walder Wyss

## Panels & pitches

Presented by  WuXi AppTec

13:00-13:45 Panel 22

Room Shanghai 3+4, level 0

### RNA therapeutics: From breakthrough science to scalable reality

RNA therapeutics are rapidly reshaping drug discovery, expanding opportunities far beyond mRNA vaccines. This panel brings together industry leaders and investors to explore how scientific innovation is translated into clinical and commercial success. From advances in RNA chemistry and delivery to manufacturing scale-up and funding strategies, panelists will share insights on key challenges and opportunities shaping the next wave of RNA-based medicines.

Moderation: **Dave Madge**, Vice President Discovery Services, WuXi AppTec

Panelists:

**Keith Philipps**, Vice President Head of Grünenthal Genetic Medicine, Grünenthal

**Hans Kistemaker**, Principal CMC Consultant, Kistemaker Pharma Consultancy

**Samir Ounzain**, CEO, Haya Therapeutics

**Sara Trifari**, CSO, T-ONE Therapeutics

**Tiziana Rossetti**, Principal, Sofinnova Partners

**Anne Grahl**, Investment Manager, Pureos Bioventures

Presented by  MOLECULAR partners

14:00-14:45 Panel 26

Room Shanghai 3+4, level 0

### How Switzerland can lead in the radiopharmaceutical industry and how to enable its full potential

For over a decade, pharma and biotech companies as well as academic centers and researchers in Switzerland have been at the forefront of nuclear medicine. As the field of radiopharmaceuticals continues to grow, we discuss how Switzerland can continue to lead and how to enable its full potential in this next era of innovation for cancer patients.

Moderation: **Philippe Girard**, Deputy Executive Director, Swissmedic

Panelists:

**Philippe Legenne**, CMO, Molecular Partners

**Andrew Cavey**, CEO, ITM Radiopharma

**Leila Jaafar**, CEO, Nuclidium

**John Prior**, Professor and Head of Nuclear Medicine and Molecular Imaging, CHUV

## Panels & pitches

Presented by **SIEMENS**

15:00-15:45 Panel 30

Room Shanghai 3+4, level 0

### Accelerating biotech: How AI, automation and virtual simulation are transforming lab design and operations

Our expert panel, featuring leaders from industry, ecosystem, and tech, who are going to delve into the transformative power of AI, automation, and virtual simulation in biotech. They will explore how these technologies are reshaping lab design and operations, discussing practical applications, benefits, challenges, and exciting future trends.

Moderation: **Jens Feddern**, Head of Life Sciences CH, Siemens Smart Infrastructure

Panelists:

**Tom Kissling**, pRED Lab Automation Partner, Roche

**Deborah Lancaster**, Partner Life Science Strategy, KPMG

**Tim Walsh**, Global Solutions Director, Siemens Smart Infrastructure

Presented by **VirdisGroup**  
INTERNATIONAL OPERATIONAL CONSULTING

16:00-16:45 Panel 34

Room Shanghai 3+4, level 0

### Talent, tenacity, and transformation: Redefining success in biotech startups

This panel dives into what it really takes to succeed as a biotech entrepreneur, from the mindset, tenacity, and skills you need to building teams that can deliver. Founders and experts share real-world lessons on tackling scientific, regulatory, and business challenges, spotting talent, and learning and adapting fast to thrive in the biotech world.

Moderation: **Natasha Konstantinova**, Head of Talent and Academy, Swiss Biotech Association

Panelists:

**Laurent Massuyeau**, Founder, iQone Healthcare Switzerland

**Nicholas Drager**, Founder and Director, Cederberg

**Nathalie Rowell**, CEO, Virdis Group

**Guido Zaman**, Founder, Oncolines

## Panels & pitches

Presented by



09:00-09:45 Panel 16

Room Singapore, level 2

### Clinical trials in Europe done right, operational excellence and smart use of scientific advice

This session provides practical insights into planning and executing clinical trials in Europe, focusing on operational excellence and strategic use of Scientific Advice. It covers efficient navigation of CTIS, including country selection, timelines, and ways to accelerate approvals while ensuring compliance. In addition, it highlights how Scientific Advice can de-risk development, align with regulators, and optimize pathways. Participants will gain actionable insights to manage complexity, avoid pitfalls, and enable timely, successful clinical development.

Moderation: **Ursula Türcke**, Senior Director Clinical Operations, FGK

Panelists:

**Stephanie Krumholz**, Founder and CEO, therainnova

**Martin Krauss**, Founder and Managing Director, FGK

Find details about the panel discussions here... →















... and about the pitching sessions here →



## Emerging biotech companies











Presented by 

Time	Company	Room Singapore, level 2
12:45	Cellvie	
13:00	Aklyox Therapeutics	
13:15	Peptone	
13:30	Red Ridge Bio	
13:45	Arphamid Therapeutics	
14:00	GliaPharm	
14:15	Shape Biopharma	
14:30	Break	
14:45	AtheBio spin-off	
15:00	ClexBio	
15:15	Nanolynx Biologics	
15:30	Biodelphis Therapeutics	
15:45	Break	
16:00	Amporin Pharmaceuticals	
16:15	Limula	

Moderation: **Veronica Gambillara Fonck**, Partner, Pureos Bioventures  
**Butrint Aliu**, Associate, Pureos Bioventures

## Clinical stage companies

Presented by 

Time	Company	Room Montreal, level 2
12:30	Celonic	
12:45	Molecular Partners	
13:00	FoRx Therapeutics	
13:15	Memo Therapeutics	
13:30	Nouscom	
13:45	AlphaMol Science	
14:00	3T Biosciences	
14:15	Diatheva	
14:30	Curatis	
14:45	Step Pharma	

Moderation: **Georg Blaser**, VP of Biologics Development Center, Celonic Group

Presented by



### 15:15-16:15 Pitch

Room Montreal, level 2

#### Reverse investor pitch

In this pitch, investors demonstrate why they stand out as strong and trusted partners for ambitious founders and high-potential businesses. They highlight the distinctiveness of their investment strategy, their hands-on approach, and the unique value they create beyond capital through expertise, networks, and long-term partnership.

Moderation: **Lorenzo Leoni**, Managing Partner, Creadd Ventures

15:15 Apollo

15:45 Creadd

15:21 BaseLaunch

15:51 Forbion

15:27 BioGeneration Ventures

15:57 Nextech

15:33 BiomedVC

















16:03 VI Partner

15:39 deepbright ventures

16:09 XGEN

## Commercial stage companies

Presented by **LONZA**

Time	Company	Room Sydney, level 2
12:30	Lonza	
12:45	Samsung Biologics	
13:00	HDI Global	
13:15	Concept Life Science	
13:30	Cytiva Europe	
13:45	Acumetis	
14:00	Genomics	
14:15	BioAgilytix	
14:30	Break	
14:45	HAS	
15:00	MSD	
15:15	Johnson & Johnson	
15:30	Ropes & Gray	
15:45	Carterra	
16:00	LIDE Biotech	
16:15	Davis Polk & Wardwell	
16:30	TwinEdge Biosciences	

Moderation: **Philipp Markolin**, Senior Manager, Integrated Biologics, Lonza

## Moderated networking tables

Presented by **DINAMIQS**  
a Seqirus company

### 12:10-12:40 Networking table 5

Room Rio, level 2

#### From science to commercialization: Can Switzerland lead the advanced therapies revolution?

Advanced Therapies (AT) have delivered remarkable clinical successes in recent years, transforming the treatment landscape for previously untreatable diseases. However, their broader impact remains constrained by significant challenges including manufacturability, scalability, consistency, and cost. This roundtable will explore the AT revolution, with a focus on cell and gene therapies and the critical role of viral vector CDMOs in enabling their commercialization. The discussion will bring together expert perspectives on how Switzerland can leverage its strengths to accelerate the translation of innovation into commercially viable therapies.

Moderation: **Luk H. Vandenberghe**, Associate Professor Harvard Medical School, Director Grousbeck Gene Therapy Center

Presented by **CLINILABS**  
the CRO with you

### 12:50-13:20 Networking table 6

Room Rio, level 2

#### How AI is accelerating drug development from discovery to clinical

Artificial intelligence is accelerating clinical development by enabling smarter trial design, faster patient identification, and real-time data insights. Across discovery and preclinical stages, AI reduces early risk by improving target selection and translational confidence. In the clinic, AI supports precision recruitment, adaptive protocols, and proactive trial monitoring – helping sponsors shorten timelines, reduce costs, and increase probability of success from first-in-human through late-stage development.

Presented by **DataArt**

### 14:50-15:20 Networking table 7

Room Rio, level 2


#### Building the intelligent trial: What it takes to scale AI across sponsors, CROs, and sites

Scaling AI across clinical trials offers substantial benefits but brings unique challenges. Join an interactive discussion led by Dmytro Baikov, VP of AI at DataArt, to explore how to incorporate and scale AI across sponsors, CROs, and sites. Assess your organization's AI maturity, share key obstacles, and identify real barriers to progress. Together, we'll develop practical, cross-industry takeaways for building AI that scales.

Moderation: **Dmytro Baikov**, Vice President of AI, DataArt  
**Sue Tripathi**, Chief Data Officer, DataArt

# Floor plan

## Level 1




## Level 0




# Floor plan

## Level 3



## Level 2



Explanation of symbols on following page

# Floor plan

- Conference rooms
  - Exhibitor booth
  - Catering
  - Barista station
  - Media table
  - Partnering helpdesk
- Partnering tables:
- pink - 1001-1030
  - blue - 2001-2050
  - purple - 3001-3050
- Photo point
  - Stairs
  - Escalator
  - Restrooms
  - Poster exhibition
  - Lounge area

## Overview of conference rooms

Name	Level	Program
Delhi	0	Panels & pitches
Kairo	0	Panels & pitches
Shanghai 1+2	0	Panels & pitches
Shanghai 3+4	0	Panels & pitches
Montreal	2	Plenary sessions   Clinical stage company presentations
Singapore	2	Emerging company presentations   Pitches
Sydney	2	Commercial stage company presentations
Rio	2	Moderated networking tables
Mexico	2	Roundtable
San Francisco	3	Global Village roundtables
Osaka/Samarkand	3	Global Village panels & pitches

Scan the QR code to access the interactive floor plan, where you can easily locate session rooms, partnering areas, and exhibitor booths. To find an exhibitor's exact location and company information, select a booth number or exhibitor name. You can also explore the partnering, panel, and pitching areas for more details.



Not sure where to go? Just ask our friendly staff in the green 'Ask Me!' T-shirts.

# Exhibitors | level 2






















## Booth Exhibitor

#1	Swiss Biotech Association	
#2	...and their friends	
#3	KBI Biopharma	
#4	Biopôle	
#5	Carbogen	
#6	CSL Behring	
#7	Fortrea	
#8	Crown Biosciences	
#8a	ICOSAGEN	
#9	Siegfried Dinamiqs	
#10	PolyPeptide Group	
#11	Comac Medical	
#12	Accelsiors	
#13	Experimental Pharmacology & Oncology Berlin-Buch	
#14	Syspro Automation	
#15	Pharmaron	
#16	Lonza	
#17	Citibank	
#18	Swissmedic	
#19	Veristat	
#20	Macrogen Europe	





















## Exhibitors | level 2

Booth	Exhibitor	
#21	Almac Group	
#22	B. Braun Medical	
#23	Quality Assistance	
#24	CROss Research	
#25	Veranova	
#26	Superlab Suisse	
#27	SGS Analytics	
#28	YUMAB	
#29	Leukocare	
#30	Celonic	
#31	Ardena	
#32	WuXi AppTec	
#33	Hamilton Bonaduz	
#34	Citeline	
#35	Philip Morris International	
#36	ICE Bioscience	
#37	FGK Clinical Research	
#38	LubioScience	
#39	Nikon	
#40	Genesupport	
		





















## Exhibitors | level 2

Booth	Exhibitor	
#41	Labcorp	
#41a	AlphaSense	
#42	Allucent	
#43	Tigermed	
#44	WuXi XDC	
#45	Clinigen Clinical Supplies	
#46	Microsynth	
#47	Stemcell	
#48	Artidis	
#49	Cytiva	
#50	Parexel	
#51	Obelysq	
#52	Worldwide Clinical Trials	
#53	MLM Medical Labs	
#54	nNano	
#55	CSEM	
#56	Hoffmann & Partner	
#57	Cetacea Clinical	
#58	Quotient Sciences	
#59	BioAgilytix	
#60	Pharmadule Morimatsu	

## Exhibitors | level 0

Booth	Exhibitor
#61	PSI CRO 
#62	BellenChem 
#63	Unchained Labs 
#64	Dottikon 
#65	Eurofins BioPharma Product Testing 
#66	White Raven 
#67	ZentriForce 
#68	Schedio 
#69	Concept Life Sciences 
#70	Neuchâtel/Fribourg 
#71	Jacobs 
#72	Onyx Scientific 
#73	Proteintech Europe 
#74	GemPharmatech 
#75	Luminance Health 
#76	Asymchem Laboratories 
#77	Pharmarketing 
#78	Clean Cells 
#79	Validated Cloud 
#80	DHL Express 

## Exhibitors | level 0

Booth	Exhibitor
#81	CRYOPDP Global Services 
#82	Neurosys 
#83	Toxstrategies 
#84	Revity 
#85	Real Chemistry 
#86	CinnaGen 
#87	Kactus 
#88	EastMabBio 
#89	Solid State Pharma 
#90	Cytion 
#91	Canfield Scientific 
#92	Sartorius Stedim 
#93	Brand Institute 
#94	Midas Pharma 
#95	Hettich 
#96	Samsung Biologics 
#97	Vector Builder 
#98	Juvion Health Sciences 
#99	Genevant 
#100	Alma Technik 

## Exhibitors | level 0

Booth	Exhibitor	
#101	Solvias	
#102	Eppendorf	
#103	Vetter Pharma	
#104	Walter	
#105	Carterra	
#106	Aptar Pharma	
#107	Farmhispania Group	
#108	Getinge Deutschland	
#109	Cube Biotech	
#110	BioPharmaSpec	
#111	Astrum CRO	
#112	Bioconcept	
#113	Arex Advisor	
#114	Yaohaibio	
#115	Productlife-Group	
#116	Diatheva	
#117	BAG Healthcare	
#118	Thermo Fisher Scientific	
#119	Bachem	
#120	ten23 Health	

## Exhibitors | level 0

Booth	Exhibitor	
#121	Space Peptides	
#122	Euromed Pharma	
#123	Kaye – Subsidiary of Amphenol	
#124	Minaris	
#125	Zeta	
#126	Richter Biologics	
#127	Genevoyager	

Find further information about the exhibitors here →



## Mentoring booths | level 3

The mentoring booths offer personalized guidance by specializing in topics relevant to biotech CEOs across the entire value chain.

Booth	Exhibitor
#MB1	Going global: International business & export Switzerland Global Enterprise 
#MB2	Non-dilutive including European funding Innosuisse & Euresearch 
#MB3	Access international R&D funding Eureka 
#MB4	Successful innovation: Entrepreneurship, collaborations, teambuilding, IP strategy Viopas Venture Consulting, Strategic Transactions Advisory, Strategic Coulter Partners, JFIPS 
#MB5	Swiss Biotech Association legal/tax/accounting: (Non-dilutive) financing Q&A Swiss Biotech Association, EY, Vischer, Homburger, WalderWyss 
#MB6	From science to deal: Optimizing enterprise value CRA International 
#MB7	Ready to turn compliance into your competitive advantage? Heidelberger & Partners 
#MB8	From local biotech innovators to global champions: Financing, M&A & IPOs Stifel 
#MB9	Accelerating healthcare through microgravity Exobiosphere 

## Swiss cluster booths | level 3

The Swiss cluster booths exhibit the innovation power of Switzerland. Selected clusters offer insight into their activities and are interested in exploring collaboration opportunities.

Booth	Exhibitor
#SC1	Università della Svizzera Italiana USI Startup Centre 
#SC2	Valais Cluster BioArk, HES-SO Valais-Wallis 
#SC3	Bern Life Science Hub BernExpo, Sitem Insel 
#SC4	Microphysiological Systems Innovation Hub Alveolix, inSphero, Mimetas 
#SC5	Biotechnet Switzerland Biotechnet, ZHAW, FHNW, University of Zurich, University of Bern, FR Institute of Chemical Technology, Swiss TPH 
#SC6	Life Science Zurich Business Network (LSZBN) LSZBN, Bio-Technopark Schlieren-Zürich 
#SC7	Image Acquisition & AI-Driven Analysis at ETH & EPFL ScopeM, EPFL 
#SC8	Lausanne Research UNIL-CHUV, Ludwig Institute 
#SC9	Swiss Clinical and Translational Research Cluster Swiss Medical Network, Genolier 
#SC10	HE-Arc   Microcity Microcity, HE-Arc 
#SC11	PULSE – Modular Life Science Center PULSE by Epic 

## Poster presentation

No.	Company	Level	No.	Company	Level
#01	Abbmira Therapeutics	1	#33	InSphero	1
#02	Adoram Therapeutics	1	#34	InVirtuo Labs	1
#03	AevX Therapeutics	1	#35	Jantar	1
#04	ALP AI	1	#36	Juvion Health Sciences	1
#05	AlveoliX	1	#37	Limula	1
#06	Amporin Pharmaceuticals	1	#38	Linkster Therapeutics	1
#07	Antion Biosciences	1	#39	Memo Therapeutics	1
#08	Asemblis	1	#40	Metys Pharmaceuticals	1
#09	Athebio	1	#41	Nanolynx Biologics	1
#10	AxCellerate	1	#42	NanThermix	1
#11	BigOmics	1	#43	NewBiologix	1
#12	Biodelphis	1	#44	NewBiologix	1
#13	Bioscibex	1	#45	Nouscom	1
#14	BioVersys	1	#46	Nuantic	1
#15	Caldre	1	#47	OM Pharma	1
#16	ChAlron	1	#48	ONtrack	1
#17	Crosswalk Therapeutics	1	#49	Onward Therapeutics	1
#18	Damian Pharma	1	#50	OptoLumina	1
#19	DiNAMIQS	1	#51	Parithera	1
#20	Elionova	1	#52	PDC Therapeutics	1
#21	Enantios	1	#53	Perseo Pharma	1
#22	EsoCap	1	#54	Pilatus	1
#23	Eviive	1	#55	Prevision Medicine	1
#24	FluoSphera	1	#56	Procavea Biotech	1
#25	FoRx Therapeutics	1	#57	Pure-DEL	1
#26	Fy Cappa Biologics	1	#58	QuantBio	1
#27	Gibela Therapeutics	1	#59	Regenera	1
#28	GlycoEra	1	#60	REM Analytics	1
#29	Hemastatx	1	#61	Selmod	1
#30	IBEX Therapeutics	1	#62	Shape Biopharma	1
#31	Immunophotonics	1	#63	Shrare	1

## Poster presentation

No.	Company	Level	No.	Company	Level
#64	Somagenetix	1	#73	TransHeps	1
#65	SpiroChem	1	#74	Trillium	1
#66	Stämm	1	#75	Twinedge Biosciences	1
#67	SunRegen Healthcare	1	#76	Visienco	1
#68	Sydra Biotech	1	#78	Xemperia	1
#69	Synameta Therapeutics	1	#79	Ymmunbio	1
#70	Synendos Therapeutics	1	#80	Beyond Genomix	1
#71	Tandem Therapeutics	1	#81	NagiBio	1
#72	TissueLabs	1	#82	Swiss Rockets	1

### Swiss Biotech Success Stories

No.	Laureate	Level
S 01	Swiss Biotech Success Stories Awards, categories & jury	3
S 02	Actelion   Patrick Aebischer	3
S 03	Werner Arber   Bachem	3
S 04	Basilea   Biogen	3
S 05	Debiopharm   ESBATech	3
S 06	FSRMM   Genedata	3
S 07	Glycart   Helsinn	3
S 08	Humabs BioMed/Vir   Etienne Jornod	3
S 09	Lonza   Henri B. Meier	3
S 10	Novimmune   Okairos	3
S 11	Selexis   Sophia Genetics	3
S 12	Hans-Peter Strebel   venture, Venturelab, Venture Kick	3
S 13	Vifor   Pascale Vonmont	3

### Where to find the posters

- Posters of Swiss biotech R&D companies are being shown on level 1
- Posters of Swiss Biotech Success Stories Award winners are being shown on level 3

There will be dedicated poster sessions on Monday, May 4, 16:15 - 17:00, and on Tuesday, May 5, 14:45 - 15:30

# Participating companies

(final - as of May 5, 2026)

• Member of the Swiss Biotech Association

Company	Country	
[lito] Business Intelligence	DE	
10x Genomics	NL	
20/20 OptimEyes Technologies	CA	
201 Therapeutics	CH	
2NA FISH GmbH	DE	
360biolabs	AU	
3BIOTECH	FR	
3CON Pharma Medical GmbH	AT	
3DBioFibR	CA	
3i Group Plc	CH	
3T Biosciences Europe GmbH	CH	•
4basebio	UK	
4Bases SA	CH	•
4G Clinical, B.V	NL	
5 Prime Sciences	CA	
59 North	UK	
7AlpsBio GmbH	CH	•
a-connect	CH	
A/S Metroserit	EE	
A&O Pharma	DE	
AB2 Bio Ltd	CH	•
Abbellight	FR	
Abbmira Therapeutics AG	CH	•
abc biopply ag	CH	•
ABCD Antibodies SA	CH	•
abcDNA GmbH	CH	•
ABclonal Biotechnology	CN/DE	
Abcured	GR	
Able Tx	IL	
Ablevia biotech	AT	
ABS Biotechnologies	AT	
Abselion	UK	
Abzena	UK	
AC Immune SA	CH	•
AcademicLabs	BE	
Acapo Onsagers AS	NO	
ACBio Marketing Consulting Sagl	CH	•
ACCELERERA Srl	IT	

Company	Country	
accela advisors	CH	
Accelsiors AG	CH	•
Access Innovation BioBridge	CA	
Accord Medica	US	
Acies bio d.o.o	SI	
Acino International AG	CH	
ACM Biosciences AG	CH	•
acmaios	DE	
Acomhal Research, Inc.	CH	
ACROBiosystems	CH	•
Actalent	CH	
Actemium	CH	
Action Community for Entrepreneurship (ACE.SG)	SG	
Acumetis	UK	
AD-MSAT biopharm	FR	
Adamastor Bioservices Srl	IT	
ADARE PHARMACEUTICALS SRL	IT	
adesso Schweiz AG	CH	
Adherent Health	DE	
Adimab	US	
Adiposs SA	CH	•
ADM International Sarl	CH	•
ADMEDDICON - DMPK Consulting	DE	
admedicum & KG	DE	
Adolf Kühner AG	CH	•
Adoram Therapeutics SA	CH	•
Adryan	CH	
Adularia AG	CH	•
Advanced Clinical Switzerland GmbH	CH	•
Advanthink	FR	
AdveNeuro SA	CH	
Advestra	CH	
Adwiss service sarl	CH	
Aerska	US	
Aesara	CH	
aevX Bio SA	CH	•
Africa Collective	CH	
Aganitha AI	IN	

# Participating companies

Company	Country	
AGC Biologics	DK	
Agilent Technologies	CH	
Agility Life Sciences	UK	
Agro-Bio	FR	
ahtida Health Clinic GmbH	CH	•
AI Global Branding	CH/UK	
AI Invest Lab	LV	
AI-Driven Therapeutics	DE	
AICEP Portugal Trade & Invest	CH/PT	
AIM	NL	
aimed analytics GmbH	DE	
AIT STUDIO	KR	
akampion	DE	
Akceso Advisors AG	CH	•
Aklyox Therapeutics GmbH	CH	•
Albor Biotech SL	ES	
Alentis Therapeutics AG	CH	•
Aleph Farms AG	CH	•
Alesta Therapeutics	NL	
Alfa Laval Mid Europe	CH	
ALGENPHARM	DZ	
Alipheron	CH	
Alira Health	DE/ES/IT	
Alira Health AG	CH	•
Alitheia Biotechnology GmbH	DE	
Alitheia Genomics SA	CH	•
ALK-Abelló	DK	
Allegis Group	CH	
Allegría Therapeutics AG	CH	•
Alltim	CH	
Allucent	UK/NL	
Almac Group	UK	•
Almasan	CH	
Almatechnik TDF	CH	
Almelo Private Limited	IN	
Alnylam Pharmaceuticals	CH	
ALP Bio AG	CH	•
Alpha Lyncis SA	CH	•
Alphalyse A/S	DK	

Company	Country	
AlphaMol Science AG	CH	•
AlphaSense	UK	
Alpinity Bio GmbH	CH	•
Altasciences	CA	•
Alter Ego biotech	FR	
Alterbiotix	CH	
Altius Consulting GMBH	CH	
Altorfer Engineering GmbH	CH	•
AlveoliX AG	CH	•
amartinez-consulting	CH	
Ambassade de France en Suisse	CH	
Amberg Group AG	CH	
Ambiotis	FR	
AmphiliX AG	CH	•
Ampleia	FR	
Amporin Pharmaceuticals AG	CH	•
AMYRA Biotech AG	CH	•
AnaPath	ES	
AnaPath	CH	•
Anapharm Bioanalytics	ES	
Anaveon AG	CH	•
AND Biotech AG	CH	•
Andreas Hettich	DE	
ANPOLY	KR	
ANSEA AG	CH	•
anteris helvetia AG - Kymanox Europe	CH	•
Antibody Analytics trading as RoukenBio	UK	
Antibody Design	UK	
ANTINEO SAS	FR	
Antion Biosciences SA	CH	•
ApconiX	UK	
Apellis	CH	
Apeloa Europe	DE	
Aphaia Pharma AG	CH	•
APICES	ES	
ApiniLabs	CH	
APMONIA THERAPEUTICS	FR	
APNC Sweden	SE	
Apollo Health Ventures	LU	

## Participating companies

Company	Country	
Approach Belgium	BE	
APR Applied Pharma Research SA	CH	●
Aptar Pharma	FR	
ArabMed CRO	SA	
Araceli Biosciences	US	
Aragen Life Sciences	IN	●
Araris Biotech AG	CH	●
Araucaria Venture	CL	
ArcanaBio ApS	DK	
Arcera Life Sciences	CH	
ARCHIMED	FR	
Arcinova, A Quotient Sciences Company	UK	
Arcondis	CH	
arcoris bio AG	CH	●
Arctoris	UK	
Ardena	BE	
Arex Advisor	CH	
Argentum Consultants	IL	
argenx BV	BE	
Aristo AG	CH	
ARKGEN BioScions	KR	
Arkivum	UK	
Arphamid Therapeutics SAS	FR	
Arriello Ireland Limited	IE	
ArtBio GmbH	CH	●
ARTCLINE	DE	
ARTIDIS AG	CH	●
Artman Technologies	SK	
Aryastha Life Sciences	IN	
Asahi Kasei Pharma Corporation	JP	
Ascelis Peptides	IN	
Ascend Advance Therapies	US	
Asceneuron SA	CH	●
Asembilis GmbH	CH	●
ASGENTO	DE	
Asia Innovation and Finance Center	CH	
Asimov	UK	
ASIO Biomedical Consulting GmbH	DE	
Aspeya Switzerland SA	CH	●

Company	Country	
Astellas	UK	
Asterale Capital	CH	
AstraZeneca	CH	
Astrum	FR/PT/DE	
ASTRUM CRO, SL.	ES	
Astrum Germany	DE	
Asymchem	US	
AT-31 BIO Inc.	KR	
ATANIS Biotech AG	CH	●
AtG Therapeutics	ES	
Athebio AG	CH	●
ATHENS LIFETECH PARK	GR	
Atlantic BioCorp	CA	
Atopia Therapeutics	CH	●
Atrogi AB	SE	
Audoban and Co	CH	
Augustine Therapeutics	BE	
Aukera Therapeutics GmbH	CH	●
Aurigon GmbH	DE	
Aurlide Oy	FI	
Aurum Biosciences	UK	
Austrade	AU/DE	
Australian Embassy Bern	CH	
Austrian Business Agency	AT	
Ausun Pharmaceutical	CN	
AUVERGNE-RHONE-ALPES ENTREPRISES	FR	
Auxenion Research AG	CH	●
Avance Basel GmbH	CH	●
AVANTECA Partners AG	CH	
AVEctivate GmbH	CH	●
Avenza Consulting Sàrl	CH	●
AVS Bio Netherlands B.V	NL	
avs engineering	DE	
AWEX - Wallonia Export & Investment Agency	BE	
AxCellerate Sagl	CH	●
axcura AG	CH	●
AXFENBIO	FR	
Axplora	DE	
Axxam SpA	IT	●

## Participating companies

Company	Country	
Azafaros Switzerland AG	CH	●
Azur Health Science	FR	
AzureCell SA	CH	●
B SQUARED Sarl	CH	●
b-communication GmbH	DE	
B. Braun Medical AG	CH	
B2B Swiss Medien	CH	
Baccinex SA	CH	●
Bachem AG	CH	●
BACHMANN FORMING	CH	
BackingHerVenture e.V	DE	
Baden-Württemberg International	DE	
BAG Health Care GmbH	DE	
Bain Capital Life Sciences	US	
Baio Labs	CH	
Baker & McKenzie LLP	UK	
Baker McKenzie Switzerland AG	CH	●
Balgrist Campus	CH	
Baliopharm AG	CH	●
Ball Pharma Consulting., LLC	US	
Bambooster	CH	
bamconn	DE	
Bank of America	UK/CH	
Banook	FR	
BAP Pharma	DE	
Bär & Karrer	CH	
Barré	BE	
Barrington James	UK	
Basel Area Business & Innovation	CH	
Basel Biotech Consulting GmbH	CH	●
Basel Convention Bureau	CH	
Basel Tourismus	CH	
BaseLaunch	CH	
Basilea Pharmaceutica AG	CH	●
Basler Zeitung	CH	
Batea Oncology	ES	
Bavarian Nordic Berna GmbH	CH	●
Baxiva	CH	
Bayer (Schweiz) AG	CH	

Company	Country	
Bayern International	DE	
BD as a Service	CH	
Becton Dickinson AG	CH	●
BeCytes Biotechnologies	ES	
Belgian Embassy / Wallonie-Bruxelles International	BE	
Bellecapital International AG	CH	
Bellen Chemistry Ltd.	UK	
Benevolent AI	UK	
Bentleys	AU	
BeOne Medicines I GmbH	CH	●
Berking Theranostics	DE	
Berlin Partner für Wirtschaft und Technologie	DE	
Bern Economic Development Agency	CH	
Bernhard Fischer Consulting and SICC	CH	
BERNINA Biolinvest AG	CH	●
bespark bio	AT	
BespokExe sarl	CH	●
Betta Scientific AG	CH	●
Beyond 20/20 Consulting GmbH	CH	●
BEYOND GENOMIX SA	CH	●
BFlow	ES	
BIA	UK	
Bicoll	DE	
BIDECO AG	CH	●
BigOmics Analytics SA	CH	●
BIIE AI Initiative AG	CH	●
BIMOVIS	DE	
Bio-Rad Laboratories AG	CH	●
Bio-ReCell d.o.o	SI	
Bio-Research.AI	KR	
Bio-Techne AG	CH	●
Bio-Technopark Schlieren-Zürich	CH	●
BIO.NRW	DE	
BIO4 Campus	RS	
BioAgilytix	DE	
BioAlps Association	CH	
Bioark SA	CH	●
BioAro	CA	
BioAudix	CH	

## Participating companies

Company	Country		Company	Country	
BioBox	CA		BIOPRO Baden-Württemberg	DE	
Biocat	ES		Biorce	ES	
BioCina	AU		BioReliance® Services	UK	
BioConcept AG	CH	●	BIOREP S.r.l	IT	
Biocytogen	CN/US		bioRN Life Science Cluster	DE	
Biodelphis Therapeutics SA	CH	●	Biosan SIA	LV	
BioDuro	US		biosaxony e.V. / leap:up	DE	
Bioengineering AG	CH	●	Bioscibex SA	CH	●
Biofactory Competence Center	CH		BIOSEB	FR	
BioFi	CH		Biosimulytics Limited	IE	
Biofidus	DE		BioSpace	US	
biogem scarl	IT		Biosynth	CH	●
Biogen International GmbH	CH	●	BiotechA	LT	
BioGeneration Ventures	NL		Biotechnet Switzerland	CH	
BioGenes	DE		Biotika a.s	SK	
Biognosys	FR		Biotrial	FR	
BioIVT	CH/DE/IT		Bious Labs	LT	
Biokanzlei	AT		BioValley Basel	CH	
BioKryo	DE		BioValley France	FR	
Biolacuna Limited	UK		BioVersys AG	CH	●
BioLingus IP II GmbH	CH	●	Biovia	BE	
BioLink Intelligence	DE		BioWorld Today	UK	
BioLizard SA	CH	●	BioX Technologies	SK	
BioM Biotech Cluster Development	DE		BioXpress Therapeutics SA	CH	●
BiomedVC AG	CH	●	BirchBioMed	CA	
bioMérieux (SUISSE)	CH		Black Diamond Networks	US	
Biomia	DK		Black Fountain Capital	CH	
BiomimX	IT		Black Label Sp. z o.o	PL	
biomindz	DE		BLACKTHORN AI	UK	
Biomine Health	ZA		Blanc-Labo SA	CH	●
BIONCaRT	DE		BLEEDnFIRE Therapeutics AG	CH	●
Bioneer A/S	DK		BLINK	DE	
Bionomus SA	CH	●	Blue Ocean Technologies	CA	
Bionrec	DE		Bluepharma	PT	
BioPark Regensburg	DE		Blueprint Medicines (Switzerland) GmbH	CH	●
Biopath Consulting	DE		BMD Life Sciences	DE	
Biopharma Group	UK		Boehringer Ingelheim International	DE	
BioPharmaSpec	DE		Bogaziçi University	TR	
Biopôle SA	CH	●	Böhler Life Science Advice	CH	●

## Participating companies

Company	Country		Company	Country	
Bonetti & Partner GmbH	CH	●	Cancer Research and Biotechnology AG	CH	●
BOOT HC	IT		Candiolo Cancer Institute	IT	
Boston Institute of Biotechnology	CN		Canfield Scientific	NL/US	
Boyden Global Executive Search	CH		Cantaluppi and Partners Sàrl	CH	
BPG Partners	CH		Canton Biologics	CN	
BRAINBiocatalysts	UK		CanVirex AG	CH	●
BRAND INSTITUTE	US		CapeBio	ZA	
Brenus Pharma	FR		Capish Nordic AB	SE	
Bright Peak Therapeutics AG	CH	●	Capture Study	LV	
Brinox d.o.o	SI		Caravel Bio	US	
Brinox Innovations	CH		CARBOGEN AMCIS	CH	
Bristol-Myers Squibb	CH		Carterra	US	
British Embassy in Switzerland	CH		Casale	CH	
Brooksmiller Partners AG	CH		Casebase Health	CH	
Bruker	CH/DE		Castomize Technologies Pte. Ltd	SG	
Bruker Daltonics GmbH	DE		Catalent Pharma Solutions	FR	
BRUN Consulting	CH	●	Catalent Pharma Solutions GmbH	CH	●
BSL BIOSERVICE Scientific Laboratories Munich	DE		Catalonia Trade & Investment	DE	
Bühlmann Laboratories AG	CH	●	Catalyze Switzerland GmbH	CH	●
Business & Economic Development, Canton of	CH		Catenion	DE	
Business Finland	DE/FI		CatSci	UK	
Business France Switzerland	CH		CBT SOFOFA Hub	CL	
Business Oregon	DE/US		CCRM	CA	
Business Parc	CH		CD4 Therapeutics	DE	
BusinessPA - Pennsylvania Investment Office	CH/DE		CDR-Life AG	CH	●
Byondis B.V	NL		CeGaT	DE	
C2 Health Consulting	CH		Celerion Switzerland AG	CH	●
Cadence Design Systems GmbH	DE		Cell and Gene Therapy Catapult	UK	
CADFEM (Suisse)	CH		Cell Environment	FR	
Caelum Bio	CH		CELL-EASY	FR	
CALDRE AG	CH	●	Cellbox Labs	LV	
CalicoBiosystems SA	CH		Cellbox Solutions	DE	
Calliditas Therapeutics Suisse SA	CH	●	CellCarta Biosciences	BE	
Cambrex Profarmaco Milano SRL	IT		Cellectricron AB	SE	
Camera di Commercio Italiana per la Svizzera	CH		Cellerna Bioscience GmbH	DE	
Campus Biotech Geneva Foundation	CH		Cellknit	KR	
Campus Technologies Freiburg	DE		CELLNTEC Advanced Cell Systems	CH	●
Canadian Mission to the EU	BE		Cellula Therapeutics SA	CH	●
			cellvie AG	CH	●

## Participating companies

Company	Country	
Celonic AG	CH	●
Cencora	CH/ES	
CENEXI	BE	
Centerview Partners	US	
Centre for Human Drug Research	NL	
Centre for Process Innovation	UK	
Centrix Pharma Solutions	UK	
CER Groupe	BE	
Cerbios-Pharma SA	CH	●
CERN	CH	
Certara	UK	
Cetacea Clinical GmbH	CH	●
CÉZAME CONNEXIONS	FR	
CGC	CH	
Chain Peptides	FI	
chAlron SA	CH	●
Charles River Laboratories	FR/DE	
CheckImmune	DE	
CheckOrphan	CH	
ChemCon	DE	
Chemelectiva Srl	IT	
Chemestmed OÜ	EE	
Chemengineering Switzerland AG	CH	●
ChemPartner	CN	
ChemRar (Shaoxing) Pharmaceutical Co., Ltd.	CN	
CHEMSPACE	UA	
Chengdu Kanghong Pharmaceutical Group	CN	
Chief Medical Officer	DE	
Children's Tumor Foundation	US	
Chime Biologics	CH	
Chinsiders GmbH	CH	
Choose Life BioTech SA	CH	●
ChromaCon AG	CH	●
Chubb Insurance (Switzerland) Limited	CH	
Cilag International	CH	
Cilcare	FR	
Cilio SAS	FR	
Cinmeio Therapeutics AG	CH	●
CinnaGen	IR	

Company	Country	
CIS Biopharma AG	CH	●
Cisema	CN	
Citeline	UK	●
Citibank, N.A., Sioux Falls, Zurich Branch	CH	●
Città di Bellinzona	CH	
CK QLS	CH	
CLARIO	CH/DE/US	
Claudia Ulbrich Consulting	CH	●
Clean Cells	FR	
CLEANGRAD D.O.O	SI	
ClearideBio Therapeutics	CH	
ClexBio AG	CH	●
Clinixel Life Sciences	IN	
Clinigen Healthcare Switzerland Sarl	CH	●
Climilabs	US	
ClinOps Advisory Turner GmbH	CH	●
Clirecon ApS	DK	
Clust-ER Health	IT	
CLUSTER SIVI. Soluciones Innovadoras para la Vida	ES	
CM Fine Chemicals GmbH	CH	●
CMAX Clinical Research	AU	
CMC & More GmbH	CH	●
CNRS	FR	
COCOON BIOSCIENCE S.L	ES	
Codebreaker	CL	
Cogitamen GmbH	CH	
Cogmotiv FlexCo	AT	
Cognizant	IN	
Cohesion Bureau, operated by BioConfidant Sarl	CH	●
CoJourney Inc	US	
Colab AccelBio I Associação AccelBio	PT	
Collaborative Drug Discovery	UK	
Comac Medical	BG	
Competitive Drug Development International Ltd.	UK	
Complyomics Sarl	CH	●
Comser	ES	
Concept Life Sciences	UK	
Conectus	FR	
Confinis AG	CH	

## Participating companies

Company	Country	
Congress Hub Bern	CH	
Connect2	CH	
Conscio Holding GmbH	DE	
Consortia Recruitment Partners GmbH	CH	●
Converge Bio	IL	
Convex Phase I unit	BG	
Cool Melon Ltd	UK	
Cooley LLP	UK/US	
Coopération Globale	CH	
Copoly.ai	CA	
CordenPharma	CH/DE	
Coris BioConcept	BE	
Cormac Sheridan	IE	
Council for Scientific and Industrial Research (CSIR)	ZA	
CPC Biotech - PSG Germany	DE	
CRA International (Switzerland) GmbH	CH	●
Cradle Switzerland AG	CH	●
CRB Group GmbH	CH	●
Creadd Ventures	CH	
CRIF	CH	
Crinetics Pharmaceuticals	CH	
CRITICA Pharmaceutical PC	GR	
Cross Research SA	CH	●
Crossroads Consultancy & Services	CH	
Crosswalk Therapeutics AG	CH	●
Crowell & Moring LLP	CH	
Crown Bioscience	NL	
Crux Biolabs	AU	
CRYOPDP	PT	
CSEM	CH	●
CSL	CH	●
CTC Resourcing Solutions AG	CH	●
Cube Biotech	DE	
Cura Therapeutics	CA	
CuraCell	SE	
Curare Swiss AG	CH	●
Curatis Holding AG	CH	●
CureDiab Metabolic Research	DE	
CureRoot	ZA	

Company	Country	
Curia Italy Srl	IT	
Curie.Bio	US	●
CView-Consult	FR	
Cybiome GmbH	CH	●
Cynbiose	FR	
Cytel	DE	
Cytion	DE	
Cytiva Europe GmbH	CH	●
Cytosurge AG	CH	●
CZ Vaccines	ES	
dabl	IE	
Daiichi Sankyo	CH/DE	
DAMIAN PHARMA AG	CH	●
Data Intelligence	CH	
DataArt	DE/US	
Datasite	CH	
Davis Polk & Wardwell	US	
De Bord International	CH	
DEASYL SA	CH	●
Debiopharm International SA	CH	●
dEEGtal Insights SA	CH	●
Deep MedChem a.s.	CZ	
Deep Tech Foundry	MT	
Deepbright Ventures	DE	
DeepLife	FR	
Defossilisation Development Fund	LU	
Delaware Consulting Switzerland	CH	
delaware Germany	DE	
Deloitte AG	CH	●
DELTA PHARMA-AL	AL	
Demcon Life Sciences & Health Eindhoven B.V	NL	
Department of Science, Technology and Innovation	ZA	
DeSC Healthcare	JP	
Development Center for Biotechnology	TW	
DEVINTEC Sagl	CH	●
Dextrial Solutions	AT	
DHL Express (Switzerland)	CH	
DIAMANTE Healthcare Consulting Sagl	CH	●
Diamics	DE	

## Participating companies

Company	Country	
Diatheva S.R.L	IT	
DiCon Press	DE	
Diex Recherche	CA	
Dimericon Therapeutics AG	CH	●
DINABIOS AG	CH	●
DINAMIQS	CH	
Discera	DE	
Discovery Studio (part of Anacura)	BE	
Diversa Technologies	ES	
DKSH Schweiz AG	CH	●
DLRC	UK	
Docupy UG	DE	
Domainex	UK	
Doordarshan India	IN	
Dottikon Exclusive Synthesis	CH	
Double Helix Technologies SIA	LV	
Dow	CH	
Dr. Paul Lohmann GmbH & Co. KGaA	DE	
Dr. Reddy's Laboratories	CH	
DragonIT GmbH	CH	●
Drug Information Association (DIA)	CH	
DRUGABILIS	FR	
DryLabz	CH	
dsm-firmenich	CH	
DTI-Tech	CH	
Duponte	ES	
Dutch Embassy	CH	
dynamXIP	CH	
E. Blum & Co AG	CH	
EastMabBio	CN	
Ecolab Schweiz	CH	
Economic Affairs - Bern Economic Development	CH	
Economic and Trade Office of the Spanish Embassy	CH	
Economic Development Partnership of North	US	
Economic Promotion Canton of Schaffhausen	CH	
Economic Promotion Canton of Zug	CH	
Economic Promotion Valais	CH	
EDELRIIS	FR	
EdgeOne Venture Partners	US	
EFAPLEX SWISS	CH	
Eldian Biomed	CH	
ELEKS SWITZERLAND	CH	
Element Eleven	BE	
eleva	DE	
ELI LILLY	CH	
Elionova AG	CH	●
Elsevier	DE	
Elthera AG	CH	●
EM Ventures	CH	
Embassy of Canada to Switzerland and Liech-	CH	
Embassy of Chile	CH	
Embassy of Finland	CH	
Embassy of Finland in Austria	AT	
Embassy of Japan	CH	
Embassy of Lithuania in Switzerland	CH	
Embassy of Portugal	CH	
Embassy of Slovenia	CH	
Embassy of Sweden in Switzerland	CH	
Embassy of Switzerland in China	CN	
Embassy of the Kingdom of the Netherlands in	CH	
Embassy of the Republic of South Africa in Brussels	BE	
Embassy of the Slovak Republic	SK	
Embion Technologies SA	CH	●
Emed Pharma	CH	
emergee	CH	
EmVenio	NL	
Enable Biotech AG	CH	●
Enamine	UA	
Enantios AG	CH	●
Endok S.r.L	IT	
ENDOK srl	IT	
Endotell AG	CH	
Endpoints News	UK	
Engimmune Therapeutics	CH	
Ennovate Pharma	FR	
Ensu GmbH	CH	●
Enterprise Estonia / Invest Estonia	EE	
enterprise ireland	CH	

## Participating companies

Company	Country	
Enterprise Singapore	SG/UK	
Enzene Inc.	US	●
EPFL	CH	
EPICS GmbH	CH	●
EpiCure	DE	
EpiDisease SL	ES	
Epiqure AG	CH	●
EPO Experimental Pharmacology and Oncology	DE	
Eppendorf SE	DE	
EquipNet LTD	CH	
EquipNet LTD c/o Meier Partner Tax AG	CH	
EraCal Therapeutics Ltd	CH	●
ERBC GROUP	FR	
Ergomed Group	UK	
Ernst & Young AG	CH	●
EsoCap AG	CH	●
Estonian Ministry of Foreign Affairs	EE	
Etablissement Français du Sang	FR	
Etablissement Français du Sang BFC	FR	
ETAP-LAB	FR	
ETH Zurich	CH	
Ethris	DE	
ETOILE CAMEROUN "ETOICAM" SARL	CM	
Eureka Network	BE	
Euresearch	CH	
Eurofins ADME BIOANALYSES	FR	
Eurofins BioPharma Product Testing Switzerland AG	CH	●
Eurofins Discovery	DE	
Eurofins Optimed	FR	
Eurofins Professional Scientific Services Switzerland	CH	●
Euromed Pharma	FR/IT	
European Molecular Biology Laboratory (EMBL)	DE	
European Pharmaceutical Students' Association	BE	
Eusyna GmbH	CH	●
eversyn	DE	
Evestia Clinical	UK	
Eviden AG	CH	●
Evidenze Health Srl	IT/ES	
EVIIVE AG	CH	●
Evitria AG	CH	●
EvviaBio AG	CH	●
Evogence Biologics Oy	FI	
EVOLVE	AR	
EVOMEDIS	AT	
Evonik	DE	
EVOTEC	DE/FR	
ExcellGene SA	CH	●
Excelsior Biopharma	TW	
Exellom Biosciences	FR	
Exobiosphere	LU	
Exocure AB	SE	
Expecto Health Science	SG	
Experimentica	FI/LT	
Expertinova AG	CH	●
Explicyte	FR	
Eyam Health	CA	
ezCaretech	KR	
F. Hoffmann-La Roche AG	CH	●
FaaS Capital Switzerland	CH	
FairJourney Bio	PT	
Famar Health Care Services Madrid S.A.U	ES	
Farinha Guedelha Executive Network Health - GenH	CH	●
Farma Mondo	CH/LT	
Farmhispania Group	ES	
Farmoquímica del Pacifico	CL	
FatiAbGen International GmbH	CH	●
FB Global Regulatory Consulting and Coaching	CH	●
Federal Department of Defense, Civil Protection and	CH	
FEED AI	DE	
Ferring International Center	CH	
FGK Clinical Research	DE	
FHNW School of Life Sciences	CH	
Fida Biosystems ApS	DK	
Fidelio Healthcare Partners	DE	
FimmCyte AG	CH	●
Finanz und Wirtschaft / Tamedia	CH	
Firalis Molecular Precision	FR	
Firefinch Software	UK	

## Participating companies

Company	Country	
Fischer PreclinTox Consulting	CH	●
FIT (Fondation pour l'innovation et la technologie)	CH	
FITODENTA	LT	
Five Office	CH	
Flanders Investment & Trade	FR	
Flex Databases	CZ	
Flikweert Data & Bioprocess Consulting	CH	
floatz GmbH	CH	●
FloBiotech GmbH	CH	●
Flomics Biotech	ES	
Florin Muraru	CH	
FluoSphera SA	CH	●
FOCALIS	IT	
Fold AI	AU	
Foley & Lardner LLP	US	
FONDATION SOPHIA ANTIPOLIS	FR	
Fondazione del Piemonte per l'Oncologia	IT	
Fongit	CH	
FONGIT - Fondation Genevoise pour l'Innovation	CH	
Food Brewer	CH	
Forbion	NL	
Fördergesellschaft IZB mbH	DE	
Fortrea	CH	●
Fortrea	ES/NL/DE	
Forty51 Advisors AG	CH	●
FoRx Therapeutics AG	CH	●
Foundation Immune Engineering for Global Child	CH	●
Fractional CSO	CH	
FrankfurtRheinMain	DE	
Fraunhofer-Institute for Toxicology and Experimental	DE	
Fresenius Kabi	CH	
freshcom	CH	
Fribourg Development Agency	CH	
Frontage Europe S.r.l	IT	
FTI Consulting	FR	
Fuchs Patentanwälte Partnerschaft mbB	DE	
Fujifilm Biotechnologies	UK	
Fundess	DE	
Fusix Biotech	DE	

Company	Country	
FUST Lab	KR	
Future Health Pharma GmbH	CH	●
futureSAX	DE	
Fy Cappa Biologics AG	CH	●
FyonBio	DE	
G-Med Consulting	CN	
Gabather AB	SE	
GaeaOU	EE	
Galapagos	CH	●
Galileo Research	IT	
Gaiser SA	CH	●
Ganda Business Solutions AG	CH	●
GBA Pharma GmbH	DE	
GBiotech Särl	CH	●
GDuvey Consulting	FR	
Gemeinde Köniz	CH	
GemPharmatech	CN/US	
GenAlz	CA	
GeneCell Studio	DE	
Genedata AG	CH	●
Genentech	US	
Genesupport SA	CH	●
Geneva Business School	CH	
Genevant Sciences GmbH	CH	●
Genevoyager	CN	
Genius Search	DE	
Genolier Innovation Hub	CH	
Genomics	UK	
Genomill Health	FI	
genOway	FR	
Genpact	CH	
GenScript Biotech (Netherlands) B.V	NL	
GenSearch Switzerland	CH	●
GenSensor	FR	
Gerresheimer	DE	
GETEC PARK.SWISS	CH	
Getinge	CH/DE	
GHF - Golden Heart Flower Ltd.	SZ	
Gibela Therapeutics GmbH	CH	●

## Participating companies

Company	Country	
Giblot Food and Health	CH	
Gilles Chatelin	CH	
GlassMedical ai Schweiz GmbH	CH	●
GilaPharm SA	CH	●
GlintMed Innovation	TW	
GlioCART GmbH	CH	●
Global Data	UK	
GlobalData Media	UK	
Gly Com SA	CH	●
Glycanostics	SK	
GlycoEra AG	CH	●
GlycoThera Analytics	DE	
GlyProVac	DK	
gMendel	DK	
GMP Bridge	CH	
GMP-Verlag Peither	DE	
GMP4U GmbH	CH	●
Gnosis Bioresearch	CH	
GO-Pen ApS	DK	
GoingPublic Media AG - Plattform Life Sciences	DE	
Gouya Insights & KG	AT	
Grand River Aspetic Manufacturing	US	
Granite Bio AG	CH	●
Granzter Regulatory	DE	
Graphene Square Chemical	KR	
Greater Geneva Bern area	CH	
Greater Zurich Area	CH	
Greaves Brewster LLP	UK	
GROUPE PRODUCTLIFE	ES/FR	
GRÜNECKER Patent Attorneys and Attorneys-at-Law	DE	
Grünenthal	DE	
GSMN Swiss Medical Network	CH	
GT Gain Therapeutics SA	CH	●
Gubra	DK	
Gubra	CH	●
H.MedicGear	KR	
H&B Real Estate AG	CH	
H4	CH	
Hadean Ventures	NO	

Company	Country	
Hamilton	CH	
HAMILTON BONADUZ	CH	
Harmony Clinical Research BV	BE	
HAS Healthcare Advanced Synthesis SA	CH	●
Haute Ecole Arc Ingénierie	CH	
Haya Therapeutics SA	CH	●
HBC HeppBiotechConsulting	CH	●
HBIO	GR	
HBM Partners AG	CH	●
HDI Global SE	CH/DE	
headcount AG	CH	●
Healiva SA	CH	●
Health and Life Sciences Cluster	BG	
Health Cluster Portugal	PT	
Health for all	CH	
Health Holland	NL	
HealthAI	CH	
HealthCare Royalty	US	
Healthcon AG	CH	●
HealthSeed	CH	
Heidelberg & Partners GmbH	CH	●
Heidrick & Struggles	CH	
HekeTiss SA	CH	●
Helical	LU	
Helix Life Sciences SA	CH	●
HELLENIC BIOCLUSTER	GR	
Helmes AS	EE	
Helsinn Healthcare SA	CH	●
Helvetic Consulting GmbH	CH	●
Hemastatx GmbH	CH	●
HEMEX (Switzerland) AG	CH	●
Herman & partnerijl SK, d.o.o	SI	
HES-SO Valais-Wallis	CH	
Hesyra-Medical GmbH	CH	●
Hettich AG	CH	●
High Force Research	UK	
Hippocrates Research Swiss SA	CH	●
Hlx Life Sciences	CH	
H02Rx	US	

## Participating companies

Company	Country		Company	Country	
Hoffmann & Partner AG	CH	●	ILIAS Biologics	KR	
Homax Advisory Sarl	CH	●	iLife Consulting	BG	
Homburger AG	CH	●	Illarion AG	CH	●
Hong Kong-Shenzhen Innovation and Technology	CN		ILLUMINA	CH	
Horgen Labs GmbH	CH	●	Ilonov Therapeutics AG	CH	●
House of Lab Science AG	CH	●	IMAGO-MOL Cluster	RO	
HTCR-Services	DE		Imapac	UK	
HUB Organoids B.V	NL		Immitra Bio GmbH	CH	●
Human in the Loop GmbH	CH	●	ImmuneWatch	BE	
Humanity Styria	AT		ImmunOs Therapeutics AG	CH	●
Humanitas Research Hospital	CH		ImmunSkills SA	CH	●
Humion	CH		IMOON THERAPEUTICS	FR	
Hungarian Biotechnology Association	HU		IMP	DE	
Hüstebeck	DE		IMPAG AG	CH	●
hVIVO	UK		Impingo Sarl	CH	
Hybrigenics Services	FR		Imunaris GmbH	CH	●
iBody	JP		In Virtuo Laboratories SA	CH	●
ICE Biopharma GmbH	CH	●	in-spectrum e.U.	AT	
ICE Bioscience	CN/US		InCephalo AG	CH	●
ICE ITALIENSICHE AGENTUR FÜR AUSSENHANDEL	CH		InCino s.r.o	CZ	
ICEX ESPAÑA EXPORTACION E INVERSIONES	ES		Incyte Biosciences International Sàrl	CH	●
ICON Clinical Research (Switzerland) GmbH	CH	●	Indivi AG	CH	
ICON Clinical Research España SL	ES		Industrial Research Assistance Program (IRAP)	CA	
Icosagen	EE		Inferre Consulting	CH	
ICTA	FR		Infinity Communications Sarl	CH	●
ICTA PM	FR		Inflexion	UK	
iCure SA	CH	●	Informa	DE/UK	
IDA Ireland	CH		infoteam Software	CH	
IDDI	BE		Ingenza	UK	
IDEXX Bioanalytics	DE		INITIS SMO	FR	
Idiomatic Bio	DK		INK Global	CA	
Idorsia Pharmaceuticals Ltd	CH	●	Inkocell	CH	
IDT Biologika	DE		InkVivo Technologies AG	CH	●
Igaidi AS	NO		INNEXIS Holding & . KG	DE	
iGii (a trading name of Integrated Graphene )	UK		InnoCore Pharmaceuticals	NL	
Ignited Vision	CH		InnoCres Consultancy	DE	
IHMA Europe	CH		InnoMedica Holding AG	CH	●
iktos	FR		Innosiamo AG	CH	●
IL-CSM Clinical Supplies Management	DE		Innosuisse	CH	

## Participating companies

Company	Country		Company	Country	
InnovationLab GmbH	DE		Investment and Development Agency of Latvia	LV	
Innovationsförderung, AWA, Kanton BS	CH		Invitris GmbH	DE	
Innovaud	CH		iOMEDICO	DE	
Innovian Space	US		iOrganBio	US	
INOFEA AG	CH	●	IPRATECH	BE	
Inotiv	DE/US		IPS Biopharma AG	CH	●
Inoviem Scientific SAS	FR		IPS-Integrated Project Services GmbH	CH	
Inovotion	FR		iPsomics	NL	
Inpharmatis SIA	LV		iQone Healthcare Switzerland SA	CH	●
Inqaba Biotechnical Industries (Pty)	ZA		IQVIA AG	CH/UK/DE	●
inscreenex	DE		IR Innovate Research Pvt	IN	
Inselspital	CH		IRBM	IT	
InsideReg Sarl	CH	●	IRCCS Centro Cardiologico Monzino	IT	
Insilico Medicine	US		Iris Biotech	DE	
InSilicoTrials	IT		Iron Bridge	DE	
Insocius Limited	UK		Ironwood Pharmaceuticals	CH	
InSphero AG	CH	●	ISIS IC GmbH	DE	
Institute of Life of Sciences, HES-SO Valais	CH		ISOREA AB	SE	
Institute of oncology research	CH		Isospec Analytics SA	CH	●
Institute of Science and Technology Austria	AT		Istituto Europeo di Oncologia (IEO)	IT	
Integra Biosciences AG	CH	●	Italian Consulate in Zurich	CH	
IntegraGen	FR		ITM	DE	
InterAx Biotech AG	CH	●	ITOCHU Europe PLC	UK	
International Drug Development	FR		ITR Laboratories	CA	
International Market Access Consulting	CH		IWATA LABEL Europe	DE	
InTheKnow PharmaSolutions	CA		J. Lamarck Asset Management SA	CH	●
Intralink	UK		Jacobs Switzerland GmbH	CH	●
INTRIALS PESQUISA CLINICA LTDA	BR		JAFRAL d.o.o	SI	
Intuitus GmbH	CH		Jantar GmbH	CH	●
Inven2	NO		Japan External Trade Organization	JP/CH	
Inventicia GmbH	CH	●	Jeffries IP	CH	●
Invest & Trade Western Australia	UK		Jericho Sciences	US	
Invest Hong Kong	CN		JETEMA	KR	
Invest in Bavaria	DE		JFG Life Sciences Stiftung der Universität Basel	CH	●
Invest in Skåne	SE		JFIPS	CH	
Invest Kong Kong	CN		Jiuzhou Pharmaceutical	DE	
Invest Lithuania	LT		Johnson & Johnson	CH	
Invest Region Leipzig	DE		Jones Lang LaSalle SE	DE	
Investissement Québec	CA		JPP - Life Sciences Marketing & BD	NL	

## Participating companies

Company	Country	
Jubilant Discovery Services LLC	US	
Julius Clinical	NL	
Jungle Biolabs	US	
Just-Evotec Biologics	UK	
Justin Stindt Consulting AG	CH	●
Juvion Health Sciences SA	CH	●
K-Recruiting Schweiz	CH	
k2p PharmaCon	DE	
KACTUS	US	
Kahimmune Therapeutics	FR	
Kanghong Pharmaceutical Group	CN	
Kanton Aargau, Standortförderung	CH	
Kapadi	US	
Kapelan Bio-Imaging	DE	
KataX	FR	
Katana Labs	DE	
KATZAROV S.A. - Patent & Trademark Attorneys	CH	
Kaye - Subsidiary of Amphenol	DE	
KBI Biopharma SA	CH	●
KCAS Bio	FR	
Kellerhals Carrard	CH	●
Kemwell Biopharma Pvt	IN	
KennedyFitch (KF) AG	CH	●
KERRY	IE	
KHANU Fondsverwaltung	DE	
KIAT	BE/KR	
KIMIALYS	FR	
KinSea Lead Discovery AS	NO	
KINSY	ES	
Kisco Sarl	CH	●
Kissei America	US	
Kistemaker Pharma Consultancy B.V	NL	
Kither Biotech	IT	
Klaster LifeScience Krakow Foundation	PL	
Klinea Biotech and Pharma Engineering	ES	
KMSLab Co., Ltd	KR	
Knowbio	DE	
knowing01 GmbH	DE	
Komtur Pharmaceuticals e.K	DE	

Company	Country	
Konapharma AG	CH	
Konexio Biotech S.L	ES	
Korea Institute for Advancement of Technology	KR	
Korea Trade-Investment Promotion Agency	KR	
KOTRA	CH/DE	
Kowa Pharmaceutical Europe AG	CH	●
KPMG AG	CH	●
KreaMedica	CA	
Kriphthonite Therapeutics	DK	
KriSan Biotech	TW	
Kromer Consulting	DE	
Kurma Partners	FR	
KVALITO AG	CH	●
Kymanox Corporation	US	
Kyorin Pharmaceutical	DE	
L-BASE	KR	
LabConnect	CH/DE	
Labcorp Central Laboratory Services Sàrl	CH/FR/UK/US	●
Labena	SI	
Labor LS SE & . KG	DE	
Laboratoire CEVIDRA	FR	
Lamprecht Pharma Logistics	CH	
Landmark BioVentures AG	CH	●
Lanya Chemical Europe GmbH	DE	
Latvian Council of Science	LV	
Latvian Institute of Organic Synthesis	LV	
Latvijas Universit te (University of Latvia)	LV	
Lausanne University Hospital	CH	
Lead Discovery Center	DE	
Leads To Development	FR	
leadXpro AG	CH	●
Leanbio, S.L	ES	
Lederer & Partner AG	CH	●
LEGIAPARK S.A	BE	
Leica Microsystems (Schweiz)	CH	
Leman Biotech Lausanne SA	CH	●
Lemna Bio SA	CH	●
Lenus Health GmbH	DE	
leon-nanodrugs GmbH	DE	

## Participating companies

Company	Country	
Leukocare	DE	
LFB Biomanufacturing	FR	
LGC Standards	IT	
Liage Benelux BV	NL	
Libera Bio S.L	ES	
Lichtsteiner Foundation	CH	
LIDE Biotech	CN	
Life Code GmbH	CH	
Life Science Cares Switzerland	CH	●
Life Science Communication AG	CH	
Life Science Nord	DE	
Life Science Zentrum Mainz	DE	
Life Science Zurich Young Scientist Network	CH	
Life Sciences Real Estate Limited	IE	
Life Sciences Switzerland	CH	
LifeSci Advisors	CH	
Lifesome Therapeutics	ES	
Light Chain Bioscience - NovImmune SA	CH	●
Lilly Deutschland	DE	
LimmaTech Biologics AG	CH	●
Limula SA	CH	●
Linear Clinical Research	AU	
LINK Medical	FI/NO	
Linkster Therapeutics AG	CH	●
LINNEA	CH	
Lino Biotech	CH	
LIQID Medical	ZA	
LISAvienna	AT	
LithuaniaBIO	LT	
Livinoeva GmbH	CH	●
Longgenesis	LV	
Lonza AG	CH/UK	●
LoopLab Bio	AT	
Losan Pharma	DE	
LOTRI Metrology	SI	
LOTTE Holdings	JP	
Loyal VC	CH	
Loyens & Loeff Switzerland LLC	CH	
LSCN	DE	

Company	Country	
LSZYSN	CH	
LTZ Therapeutics	CN/DE	
LubioScience GmbH	CH	●
Lucerne University of AS	CH	
LUCID Analytics AG	CH	●
Lucideon Group	UK	
Ludwig Institute for Cancer Research	CH	
Luko laboratorija MB	LT	
LuminaBio Advisory Sàrl	CH	
Luminance Health AG	CH	●
Lumis International	DE	
Lupin Manufacturing Solutions	UK	
Luye Pharma Switzerland AG	CH	●
Luyef Biotechnologies	CL	
Luzsana Biotechnology Europe	CH	
LxBio Pharmaceuticals	PT	
LynxKite Bio	SG	
M&G Advisors	CH	
MabDesign	FR	
Mabion S.A	PL	
Mabylon AG	CH	●
Macrogen Europe GmbH	CH	●
Madrigal Pharmaceuticals	CH	
Magma Science	PT	
Magnostics	IE	
MAI CDMO S.L	ES	
Malvern Panalytical	CH	
Mangisa Clinical Solution	CH	
marcommotion	DE	
Margon Management B.V.	NL	
Maria Stella Lombardi Consulting	FR	
MARTI FARM d.o.o	HR	
Marti Keller Consulting	CH	
Maruho	JP	
Matilda Cepele	AL	
Matrixome	JP	
Maxia Strategies GmbH	CH	●
Mayo Clinic	US	
mBioPharmaConsulting SAS	FR	

## Participating companies

Company	Country		Company	Country	
MBM Future Health	DE		Microbiotica Ltd	UK	
McArthur and Associates GmbH	CH	●	Microcity SA	CH	
MCE CARREL	FR		Microsynth AG	CH	●
McKinsey & Company	US		Midas Pharma	DE	
MDTB Cell Manufacturing	DE		Mikron Automation	CH	
MEDExpansion Sàrl	CH	●	Miltenyi Biotec Swiss AG	CH	●
Median Technologies	FR		Mima Research	CH	
MEDIC LABOR	SK		MIMETAS	NL	
Medical Research Council Laboratory for Molecular	UK		Minakem CDMO	FR	
Medical University of Vienna	AT		Minaris Advanced Therapies	DE	●
Mediclon	CH/SE		Ministerium für Wirtschaft, Verkehr, Landwirtschaft	DE	
Medicines Discovery Catapult	UK		Ministry of Foreign Affairs of Estonia	EE	
Medicon Valley Alliance	DK		Miphic	NO	
Medicover Integrated Clinical Services	RO		Miramoon Pharma	ES	
Medidata Solutions	UK		Mirava Bio Sarl	CH	●
MEDIS	SI		Mirum Pharmaceuticals AG	CH	●
Medistri SA	CH	●	MITOLOGICS	FR	
Medpace	US		MLM Medical Labs	DE	
Medscape Education Global	CH	●	MNDL BIO	IL	
MEDTECH INNOVATION ON ADVANCED MEDICINE	ES		Mo.re	DE	
Medvisis Switzerland AG	CH	●	ModelMole	UK	
MedXCell SA	CH	●	Moderna	CH	
Melius Organics SL	ES		Modulari-T	CA	
Memo Therapeutics AG	CH	●	Molecular Forecaster	CA	
Menarini Biotech	IT	●	Molecular Health	DE	
Merck KGaA	DE		Molecular Partners AG	CH	●
Merck Serono	UK		MoleSense Sàrl	CH	●
MERIBEL PHARMA ORLEANS	FR		Monte Rosa Therapeutics AG	CH	●
Meru Advisors	US		Moon Pharma	US	
Meso Scale Diagnostics, LLC	US		Morimatsu Italy srl	IT	
Mesoscale Discovery	CH		MosaMatrix	NL	
metaLead Therapeutics AG	CH	●	Moss Bio	KR	
MethylX	CH		Movatype Biomaterials	CH	
MetricoPharm AG	CH	●	Move Venture Consulting	CA	
Metromol SA	CH		MGRN Advisors Sàrl	CH	●
Metronik d.o.o	SI		MSD	UK	
Metronomia Clinical Research	DE		MTTlab srl	IT	
MetyS Pharmaceuticals AG	CH	●	MUGENBIO	CH	
Micro-Sphere SA	CH	●	MUNIT	CH	

## Participating companies

Company	Country		Company	Country	
Murata Electronics Europe B.V	NL		Neuro-Sys	FR/US	
MutaDent	CH		Neuroinnovation Ltda	CL	
MUVON Therapeutics AG	CH	●	Neurometa Therapeutics	SE	
MV BioTherapeutics SA	CH	●	New England Biolabs	DE	
MyAmici	UK		New Life Biopharma Limited	IE	
Mycenax Biotech	TW		NewBiologix SA	CH	●
Myllia Biotechnology	AT		Newcelx	CH	
Myonex	FR		NexMR AG	CH	●
MyoPax	DE		Nextech Invest	CH	
Myria Biosciences	CH		nextImpact	CH	
Naexture Research Sagl	CH	●	NextPharma Germany GmbH	DE	
Nagi Bioscience SA	CH	●	Nikon Europe B.V., Amstelveen, Zweigniederlassung	CH	●
Nanolynx Biologics AG	CH	●	NL Embassy	CH	
Nanopharm	UK		nNano	CH	
NanoSiliCal Devices s.r.l.	IT		NNIT UK	UK	
NanoTemper Technologies	DE		Noema Pharma AG	CH	●
NanoVation Therapeutics	CA		Nordic Innovators P/S	DK	
NanoZyme	CH		North Carolina Life Sciences Organization	US	
narbrains	CH		Northway Biotech	LT	
Nashville Biosciences	US		NorthX biologics	SE	
Nathalie Jenni Consulting GmbH	CH	●	Nouscom AG	CH	●
National Pharmaceutical Industries	OM		NovaGo Therapeutics AG	CH	●
National Research Council Canada	CA		Novalix	FR	
Navigo Proteins	DE		Novartis Pharma AG	CH	●
NAYA LIFE SCIENCES d.o.o	SI		Novartis Venture Fund	CH	
NBE-Therapeutics AG	CH	●	Novigenix AI SA	CH	●
Ncardia	NL		Novo Holdings	DK	
NCMA Consulting GmbH	CH	●	Novo Nordisk	CH	
ND Capital	CH		NovaArc GmbH	AT	
Neixora Partners	CH		Novotech	AU	
Neocarbons SA	CH	●	Novotech Australia Pty Ltd	AU	
Nerai Bioscience	CH	●	NRW.Global Business	DE	
Ness Therapeutics	CA		NTT DATA	IT	
Nestlé	CH		Nuantic AG	CH	●
Netherlands Enterprise Agency	NL		Nubilaria srl	IT	
Netherlands Innovation Network	DE		Nucelion Therapeutics	IN	
Neuchâtel Economy Service	CH		Nucleate Switzerland	CH	
Neuland Laboratories	CH		Nucleic Acids to the Rescue GmbH	DE	
Neurimmune AG	CH	●	Nucleus Network Ltd	UK	●

## Participating companies

Company	Country		Company	Country	
Nuclidium	CH	●	Onyx Scientific	UK	
Numab Therapeutics AG	CH	●	Open Innovation in Life Sciences	CH	
Numaferm	DE		Open Protein AI	SG	
numaH	CH		Ophthalmopro	DE	
Nuvisan	DE		OPIS s.r.l	IT	
NVIDIA	CH		Oppenberg CMC Consulting	CH	
Nxera Pharma Co., Ltd., Tokyo, Basel Branch	CH	●	Opterion Health AG	CH	●
NXI Therapeutics AG	CH	●	Optima pharma	DE	
ObelysQ SA	CH	●	OptoLumina AG	CH	●
OCCIDENT	DE		ORACTIVE Swiss AG	CH	●
Oculus Holding AG	CH	●	Oregon Health & Science University	US	
Odgers	CH		Oregon Life Sciences	US	
Oechsler AG	DE		Oregon State University	US	
OenoHealth	CH		Oriente SA	CH	●
Oertel Beratung	CH		Orion Biotechnology Switzerland	CH	●
Office of Economy and Labour, Canton of Basel-	CH		Ortho-Design PTY	ZA	
OHMX.bio (part of Anacura)	BE		Oryl Photonics SA	CH	●
Olgam SA	CH	●	Oslo University Hospital and University of Oslo	NO	
Olink Proteomics/ part of Thermo Fisher Scientific	CH		Österreichische Wirtschaftsdelegation für die	CH	
oloBion SL	ES		Outlook Therapeutics	CH	
Olon SpA	IT		Oxeltis	FR	
OM Pharma Ltd	CH	●	Oxford Nanopore Technologies plc	UK	
Omega Funds	LK		P4 precision medicine	UK	
OMNI Life Science GmbH	CH	●	P95 B.V	BE	
OmnilinX Therapeutics AG	CH	●	PacBio	CH	
Omnivision AG	CH		palleos healthcare	DE	
Oncode Accelerator	NL		Palto Therapeutics AG	CH	●
Oncodesign Services	FR	●	Panome Bio	US	
Oncoinvent	NO		Paras Biopharmaceuticals Finland Oy	FI	
Oncology Institute of Southern Switzerland	CH		Pareto Securities	CH	
Oncology Research Expertise	FR		Paroxel	US	
Oncosyne	NO		Parithera SA	CH	●
OneBio Innovation Centre	ZA		Partex.AI Labs	DE	
ONESOFTDIGM	KR		Parthen Meeting Services	NL	
Onesoftdigm (OSD)	KR		Particle Measuring Systems AG	CH	
Oniria Therapeutics	ES		Paspigioni	UK	
Ono Pharmaceutical	UK		Patifina	CH	
Ontrack Biomedical AG	CH	●	PatrickToxConsulting	FR	
Onward Therapeutics SA	CH	●	Paul Scherrer Institut	CH	

## Participating companies

Company	Country		Company	Country	
PCI Pharma Services	US/UK		PIMS Technology SAS	FR	
PDC Therapeutics SA	CH	●	Piramal Pharma Solutions	US	
Pegasus Biotechnology	CA		Pivot Park Exploitatie BV	NL	
Pensatech Pharma	DE		Pixelpharma	CH	
Peptone Switzerland AG	CH	●	PKNM Solutions Sàrl	CH	
PerfeTTO Network	IT		Planetary SA	CH	●
Permanent Mission of the Republic of Estonia to	CH		PLL Therapeutics	FR	
Perseo Pharma AG	CH	●	PLX Healthcare Services (Schweiz) GmbH	CH	●
Pestalozzi Attorneys at Law	CH		PME	CH	
Pewman Innovation	CL		PMS Process Management System Sàrl	CH	●
Phage Lab	CL		PMT - Pôle des microtechniques	FR	
Pharma Consulting ENABLE GmbH	CH	●	Pohang University of Science and Technology	KR	
Pharma Excipients International	CH		Pohang-City	KR	
Pharma Holdings AS	NO		Polyceutix	DK	
PharmaBiome AG	CH	●	Polymaterials AG	DE	
PharmaBlock Sciences (Switzerland) AG	CH	●	PolyPeptide Group	CH	●
PharmaCamp	CH		PolyPeptide Group	SE/BE	
PharmaKorell GmbH	CH	●	Populus Bio Sàrl	CH	●
PharmAla Biotech	CA		Porsoit	FR	
PharmaLegacy Laboratories (Shanghai)	CN		Portfolio Careers Hub	CH	
PHARMALEX	FR		Porton Pharmaceutical Chemicals GmbH	CH	●
PharMarketing GDPR Life Sciences	FR		PPT Pharma Process Technology AG	CH	
Pharmon, Inc.	UK	●	PQE (Suisse) Sagl	CH	●
Pharmassist	GR		Praed Pharmaceuticals Ltd	CH	●
Pharmacube Group	CN		PRC Comunicare la Scienza	CH	
Pharmidex	UK		PreciMUNE - UNIL/CHUV spin-off	CH	
Pharmify B.V.	NL		Precise Health SA	CH	●
PharmInsight	CH		Precision for Medicine	UK	
Pharmora	UK		Preclina	KR	
Pharvaris GmbH	CH	●	Premier Research	US	
PHC Ventures	CA		Prestige Clinical Packaging	DE	
Phialogics	CH	●	Prevision Medicine AG	CH	●
Philip Morris Switzerland Sàrl	CH	●	Priavoid	DE	
PHINE Bio AG	CH	●	PricewaterhouseCoopers AG	CH	
Phoenix CR	AE		PRIME - University of Toronto	CA	
PHT International Limited	US		Prinsus Spin-off Company	GR	
PI Health Sciences	IN		PRINTING AND PACKAGING SOLUTION S.L	ES	
Pictet Alternative Advisors	CH		PRIOT d.o.o	SI	
Pilatus Biosciences SA	CH	●	Probio Technology BV	NL	

## Participating companies

Company	Country	
ProBioGen	DE	
Procam Videoproductions	CH	
Procavea Biotech AG	CH	●
ProChile	DE	
ProJect Pharmaceuticals GmbH	DE	
Promega AG	CH	●
PROMOS - Agenzia italiana per	IT	
Protect Animal Health	TW	
Proteintech	UK	
ProteoGenix	FR	
Proteros biostructures	DE	
ProVasctec	IE	
Provectis Healthcare AG	CH	●
PSG Dover	DE	
PSI CRO AG	CH	●
PULSE developed by EPIC SUISSE SA	CH	●
Pure-DEL	CH	
Pureos Partners AG	CH	●
Purovid GmbH	CH	
Q Close Solutions	CH	
Q DOT Suisse	CH	
Qanatpharma AG	CH	●
QBDC GmbH	CH	●
QIAGEN	DE	
Qinos	CH	
Qity	BE	
QPS	NL	
Quality Assistance	BE	
Quant Biomarkers AG	CH	●
Quanterix	US	
Quantoom Biosciences	BE	
QUASAR Therapeutics / University of Ulm Medical	DE	
Quinn- The AI Scientist	US	
QULLA	CH	
Quotient Sciences	UK	●
CurieGen B.V	NL	
radiomics.bio	BE	
Rados Recruiting	DE	
Raffles Pharmatech	CN	

Company	Country	
Rambam AG	CH	●
Rancho BioSciences	US	
Randox Laboratories	UK	
Rapid Novor	CA	
Rappi Pharma and Health Consulting GmbH	CH	
Rare Crew	SK	
RC Tritec AG	CH	●
RCJ Unlimited - Karge Consulting	CH	
Reaction Biology Europe	DE	
Real Chemistry	UK/US	
Real Chemistry GmbH	CH	●
Recipharm Advanced Bio	PT	
Reciprocal Space	UK	
REDRIDGE BIO	CH	
Regenera SA	CH	●
Region Skåne	SE	
Reign One Capital	MN	
Release Therapeutics SA	CH	●
REM Analytics SA	CH	●
ReMedCo AG	CH	
REMORA BIOTECH FRANCE	FR	
Remora Biotech SA	CH	●
RENOLIT SE	DE	
RENTSCH PARTNER	CH	
Rentschler Biopharma SE	DE	
Repertoire Immune Medicines (Switzerland) AG	CH	●
REPROCELL EUROPE	UK	
Research Council of Lithuania	LT	
Research PIECES	FR	
Resolian	UK	
Resonant Clinical Solutions	DE	
RespAct GmbH	CH	●
Reuters	CH	
Revnuu GmbH	CH	●
Revvity	CH/DE/FR/NL	
Rezon Bio	PL	
RH Consulting	CH	
Rhyforce AG	CH	
RhyGaze AG	CH	●

## Participating companies

Company	Country	
RIANA Therapeutics	AT	
Richter BioLogics	DE	
Ridgeline Discovery	CH	
Risklick AG	CH	●
Rivia	CH	
Robeauté	FR	
Roche	DE	
Roche Diagnostics France	FR	
Rockstone Engineering Switzerland Sàrl	CH	●
Rödl AG	CH/DE	
Rodon Biologics	PT	
ROKIT HEALTHCARE	KR	
Roland Berger	CH	
Ropes & Gray	US	
Roquette Health & Pharma Solutions	FR	
Rothschild & Co	FR	
Rottendorf Pharma	DE	
RoukenBio	UK	
Royalmount BioPharma Services	CA	
S.Olweya Engineering	CH	●
Sachs Associates Switzerland AG	CH	
Sagitta Biotech	BE	
Sai Life Sciences	IN/US	
Salipro Biotech	SE	
Salvina Therapeutics AG	CH	●
Samsung Biologics	US	
Santero Therapeutics	BE	
Santhera Pharmaceuticals (Schweiz) AG	CH	●
Sanyou Biopharmaceuticals	CN	
Sartorius Stedim Biotech	DE	
Sartorius Stedim Switzerland AG	CH	●
Sartorius/Mattek	FR	
SAS BOTdesign	FR	
SATW	CH	
SaxoCell	DE	
Saxony Trade & Invest	DE	
SBMC Smart BioMaterials Center	NL	
Scantox Denmark Aps	DK	
Schedio SA	CH	●

Company	Country	
Schellenberg Wittmer	CH	
Schrödinger	DE	
scienceindustries	CH	
ScienceValue Heidelberg (SVH)	DE	
Sciensus	CH/UK	
Sciential	NL	
Sciento Technology	UK	
Sciomics	DE	
SCOPE Consulting GmbH	CH	●
Scope International AG	DE	
ScopEM ETH Zurich	CH	
Scottish Development International	DE	
Seacross pharma	CN	
Sealantium Medical	IL	
Secoya Technologies	BE	
Securecell AG	CH	●
Seda Pharmaceutical Development Services	UK	
SEED Biosciences SA	CH	●
Seito Biologics AG	CH	●
Sekisui Chemical	JP	
Selecta Biotech SE	SK	
Selexcine	KR	
Selfdiagnostics	EE	
Selmod GmbH	CH	●
Selvita S.A	PL	
Sen-Jam Pharmaceuticals	CH	
Senn Resources AG	CH	●
Sens Vue ApS	DK	
Sentient Health GmbH	CH	
SENTV DMEDIA	SN	
SEQALIS	BE	
Seqens	FR	
SeqVision	LT	
SeraDialLogistics	DE	
SeraNovo B.V	NL	
Service de l'Économie de Neuchâtel	CH	
Servier	FR	
Servier Institute of Therapeutic Innovation	FR	
Seventure Partners	FR	

## Participating companies

Company	Country		Company	Country	
SFNV	CH		Slovak Investment and Trade Development Agency	SK	
SG-PEC	FR		Slovenia Biotech Hills	SI	
SGS	BE/ES/FR		SMALTIS	FR	
SGS Analytics Switzerland AG	CH	●	Smart	BE	
SGS Life Sciences Geneva	CH	●	Socorex Isba SA	CH	●
SGS Vitrology Limited	UK		Sodha Pharma Consulting	CH	
ShamsAI	CH		Sofinnova Partners	FR	
Shape Biopharmaceuticals AG	CH	●	Softmining Srl	IT	
Shimadzu Schweiz GmbH	CH	●	Sokol Bioconsulting	CH	●
SHRARE Technology SA	CH	●	SOLBEX GmbH	CH	●
Shuimu Biosciences	CN		Solid State Pharma	CA	
SIA PrintyMed	LV		Solothurn Economic Promotion Agency	CH	
Sichuan Huiyu Pharmaceutical	CN		Solvias AG	CH/US	●
SIDLEY	CH		Somagenetix AG	CH	●
Sidley Austin LLP	DE		SONA Swiss AG	CH	●
Sidrapex Pte	CH		Sony AI	CH	
Siegfried AG	CH		Sophia Genetics SA	CH	●
SIEGFRIED DINAMIOS AG	CH	●	Sotio Biotech AG	CH	●
Siemens Schweiz AG	CH	●	SP Clinical Consulting	CH	
sifin diagnostics	DE		Space Cargo Unlimited	LU	
Signal26 Biotherapeutics SA	CH	●	Space Pharmaceuticals AG	CH	●
Simbec-Orion	UK		Spanish Bioindustry Association - AseBio	ES	
Simbionte EE	ES		Spencer Stuart	CH	
Simcere UK	UK		Sphinx Scientific Laboratory	CN	
Sinergetica Healthcare	IT		SPILLO di Alessandro Di Domizio	CH	●
Sinfonie LSM GmbH	DE		Spinning Around Ltd	UK	
Single Cell Discoveries B.V	NL		SPIRIT Slovenia	SI	
SINO	CH		SpiroChem AG	CH	
Sitem Startup Club	CH		Springer Nature	UK	●
sitem-insel	CH		SR One	CH	
SIX Swiss Exchange	CH		SRF	CH	
SK pharmteco	US		SSI Strategy	SE	
SKAN AG	CH		STA Strategic Transactions Advisory	CH	
SKC BERATUNGSGESELLSCHAFT MBH	DE		Staat Consulting	DE	
Skills Alliance	CH/UK		Staburo	DE	
SKM-IP Schmid Krauß Kuttenkeuler Malescha	DE		Stada Arzneimittel	DE	
Skyvor Medical AG	CH	●	Stagebio	DE	
SLAS	US		STÄMM	US	
Slope	US		Stämm Vegh SA	CH	●

## Participating companies

Company	Country		Company	Country	
Starlab Schweiz AG	CH	●	Swiss Cancer Institute	CH	●
Startupticker.ch	CH		Swiss Clinical Trial Organisation	CH	
State Government of Victoria	FR		Swiss Consultant-Network GmbH	CH	●
State of Geneva	CH		Swiss Federal Institute of Intellectual Property	CH	
STATE RESEARCH INSTITUTE CENTRE FOR	LT		Swiss Health Angels	CH	
steerBIO GmbH	CH	●	Swiss Healthcare Startups	CH	
Steinecker GmbH / Kronos	DE		Swiss Life	CH	
StellarPeakSystems	CA		Swiss Medical Network	CH	
Stellenbosch University, Department of Food	ZA		Swiss Nuclear Forum	CH	
STEMCELL Technologies	CA/CH		Swiss Rockets AG	CH	●
Step Pharma	FR		Swiss Stem Cell Foundation	CH	●
Sterling Pharma Solutions	UK		SwissHikes with Yogita	CH	
Sterne Kessler	US		Swissmedic	CH	
Stifel Europe Limited	FR		Swissnex	CH	
Stiftung grow	CH	●	SwissTech	SK	
Strategic Transactions Advisory AG	CH		SwitchKine AG	CH	●
SUCCIPRO	ES		Switzerland Convention & Incentive Bureau	DE	
Summa Biotech B.V	NL		Switzerland Global Enterprise	CH	●
SunRegen Healthcare AG	CH	●	Switzerland Innovation	CH	
SunRock Biopharma S.L	ES		Switzerland Innovation Park Biel/Bienne	CH	
Superlab Suisse AG	CH	●	Swizzard Pharma AG	CH	●
Superpositions	CH		SYDRA AG	CH	●
Supply Chain Operations SA	CH	●	Sygnature Discovery	UK	
SUPSI/DTI	CH		Symbiosis Pharmaceutical Services	UK	
Sussex Research Laboratories	CA		Symcel AB	SE	
Suzhou Auxin Bio-Pharmaceuticals	CN		Symsights AG	CH	
Svar Life Science AB	SE		Synameta Therapeutics Sarl	CH	●
SwAPP	CH		SynapCell SAS	FR	
Swarm Oncology	UK		Synendos Therapeutics AG	CH	●
SwedenBIO	SE		Syneos Health Switzerland GmbH	CH	●
Swiss Biotech Association	CH	●	Synergia BIO	CL	
Swiss Biotech Center SA	CH	●	Synexa Life Sciences	UK	
Swiss Broadcasting Corporation (swissinfo)	CH		SYNGULON	BE	
Swiss Business Hub China	CN/IN		Synovo	DE	
Swiss Business Hub France	FR		SynphaBase AG	CH	
Swiss Business Hub India	IN		Synple Chem AG	CH	●
Swiss Business Hub Japan / Embassy of Switzer-	JP		SYNSMART RASAYAN RESEARCH	IN	
Swiss Business Hub Korea	KR		Syspro Automation	ES	
Swiss Business Hub UK	UK		Syspro Automation AG	CH	●

## Participating companies

Company	Country	
Syspro Automation SLU	ES	
Systemisches Institut für Führung und Beratung	DE	
T-knife GmbH	DE	
T-Oncology AG	CH	●
T-ONE Therapeutics	IT	
T3 Pharmaceuticals AG	CH	●
Tada Labs	DE	
Taisho Pharmaceutical	JP	
Taiwan Bio Industry Organization	TW	
Tak BioSuisse	CH	●
Talisto GmbH	CH	●
Tandem Therapeutics AG	CH	●
Tane AG	CH	●
Tanner Pharma	US	
TargetEx	HU	
TargImmune Therapeutics	CH	●
Taros Chemicals	DE	
Tartu Biotechnology Park	EE	
TATAA Biocenter	SE	
TBD Pharmatech	EE	
Tecan	CH	
Tech Edge Management	DE	
Technology Innovation Agency of South Africa	ZA	
TECregen AG	CH	●
Teguar	CH/US	
Telemedicine Technologies Belgium	BE	
Tempus AI	US	
ten23 health AG	CH	●
Tenpoint Therapeutics GmbH	CH	●
Terra Quantum	DE	
Terrapinn	UK	
Tetra Pak Processing Systems	SE	
Tetrakit Technologies	DK	
TFS HealthScience	SE	
The Coulter Partnership Sarl	CH	●
The Cultured Hub	CH	
The IN Group GmbH	CH	●
The Life Science Cluster	NO	
The National Research Council of Canada	CA	

Company	Country	
The Research Council of Lithuania	LT	
The Science Behind	UK	
The Tiny Pharma Company	CH	
therainnova AG	CH	●
TheraPPI Bioscience SA	CH	●
Thermo Fisher Life Technologies Europe B.V.	CH	●
Thermo Fisher Scientific - Life Technologies GmbH	DE	
Thermo Fisher Scientific Biologics Lengnau	CH/ES/NL/US	●
TIBIO Sagl	CH	●
Tigermud Swiss AG	CH	●
Tigran Arzumanov	CH	●
Tillotts Pharma	CH	
TILT Lifesciences / Zug Pharma Group	CH	
TissueLabs SA	CH	●
Tjoapack Netherlands BV	NL	
TO Therapeutics AG	CH	●
TokaBio (Pty)	ZA	
TOLREMO therapeutics AG	CH	●
TOP MIDDLE L.L.C	AE	
Topadur Pharma AG	CH	●
Torrey Pines Investment	US	
Tox Consult Basel	CH	
ToxStrategies, a BlueRidge Life Sciences Company	US	
TPM, Science & Technology Park for Medicine	IT	
TQ Therapeutics	DE	
TraceLine Solutions GmbH	CH	
TRACER Europe BV	NL	
Trade and Investment Queensland	DE	
TRAFIK Productions	UK	
Transcell Biologics	IN	
TransCrip Group Limited	UK	
TransCure bioServices	FR	
Transformiq	CH	
TransHeps AG	CH	●
Translation-X	CH	
Translational Medicine Accelerator	CH	
transMedChem GmbH	DE	
TransPerfect	US	
Transpharmation	CA	

## Participating companies

Company	Country	
Trasis	BE	
Trialyze AG	CH	●
Trillione GmbH	CH	●
Trisail Medical	SG	
Trockle Consultancy	CH	
Trophic Communications	DE	
TrustSEC Sp. z o.o	PL	
TS Kommunikation	CH	
TSafe GmbH	DE	
Tuari Therapeutics GmbH	DE	
Tulia Via GmbH	CH	
TUNECT CRO	AM	
Turbine	UK	
TwinEdge Bioscience SA	CH	●
Twist Bioscience	NL	
UAB Biotecha	LT	
UBS Switzerland	CH	
UCB Farchim SA/UCB Pharma AG	CH	●
UCLouvain	BE	
Ufficio per lo sviluppo economico Canton Ticino	CH	
UFRJ	CH	
UGA Biopharma	DE	
Ultimate Medicine AG	CH	●
ULTRACE DEVELOPMENT PARTNER	FR	
Umlaut.bio GmbH	CH	●
Unchained Labs	UK/US	
Uni Wuerzburg - TTO	DE	
Unilabs A/S	DK	
United Airlines Inc	DE	
Università degli Studi di Messina	IT	
Università degli Studi di Torino	IT	
Università della Svizzera italiana	CH	
Universität St. Gallen	CH	
Universitätsspital Zürich	CH	
Université de Namur	BE	
Université libre de Bruxelles	BE	
University Hospital Tübingen, Dermatology	DE	
University Hospital Zurich	CH	
University Medical Center Freiburg	DE	

Company	Country	
University of Applied Sciences Western Switzerland	CH	
University of Basel	CH	
University of Bern	CH	
University of Bristol	UK	
University of Cambridge	UK	
University of Coimbra	PT	
University Of Exeter	UK	
University of Fribourg	CH	
University of Geneva	CH	
University of Helsinki	FI	
University of Latvia	LV	
University of Lausanne	CH	
University of Milano-Bicocca	IT	
University of Nottingham	UK	
University of Oxford	UK	
University of Pisa	IT	
University of Zurich	CH	
Unlock Bio	CH	
UNOMR	CH	
Upperton Pharma Solutions	UK	
UZH	CH	
V2O Consulting	BE	
Vaccentis AG	CH	●
Vactech Oy	FI	
Vaderis Therapeutics AG	CH	●
Valanx Biotech	AT	
validAID GmbH	DE	
Validated Cloud BV	NL	
valuationLAB AG	CH	●
Valur Management Group	CH	
Vandria SA	CH	●
VarmX	NL	
Vaudaux-Eppendorf AG	CH	
Vaxcyte Switzerland GmbH	CH	
Vebevo AG	CH	
VectioPep	EE	
Vector laboratories	UK	
VectorBuilder	US	
VelaLabs GmbH	AT	

## Participating companies

Company	Country	
Venrock Capital Partners	US	
Venture Valuation VV AG	CH	●
VentureCapital Magazin	DE	
Venturelab	CH	
VentureScout	CH	
Veranova	UK	
VERAXA Biotech	DE	
Verdeya	CH	
Veristat	US	
Veritas In Silico	JP	
Vernalis (R&D) Limited	UK	
Versant Ventures	CH	
Versarys Bioscience	CH	
VertisPro Pte Ltd	SG	
Vetter	DE	
Vi Partners	CH	
Vianti Capital	US	
VIB	BE	
Viedoc	SE	
Vifera XS	CH	
Viking Pump Hygienic	UK	
VILS Switzerland GmbH	CH	●
Vincere Life Sciences LTDA	BR	
Viopas Venture Consulting GmbH	CH	●
vips	CH	
Vir Biotechnology, Inc. (formerly Humabs BioMed)	CH	●
ViridisGroup Sàrl	CH	●
Virella	LI	
ViroCarb	CA	
Virusure Forschung und Entwicklung	AT	
Viscacia GmbH	CH	
VISCHER AG	CH	●
Visconti Alliance Management	CH	
Visienco	CH	
Visindi	CH	
VITROCELL Systems GmbH	DE	
Vivara Life Sciences	DE	
VivoArchitect Sàrl	CH	●
VML Health	CH	

Company	Country	
Vogel BioC	CH	
Voisin Consulting CH Sarl	CH	●
Volv Global SA	CH	●
Voss	CH	
Vossius & Partner	CH	
VoxCell	CA	
VTU Engineering Schweiz AG	CH	●
VUGENE	LT	
W Biotech GmbH	CH	●
W. L. Gore & Associates GmbH	DE	
Wacker Biotech B.V	NL	
Walder Wyss AG	CH	●
Wallonie-Bruxelles International	BE	
Walter Suisse SA	CH	●
Waters Corporation	US	
Waters nv	BE	
Watson-Marlow AG	CH	●
Wave Immune	FR	
Wavemedix Inc.	CH	
wega Informatik AG	CH	
Wellington Partners LS VC	DE	
Wemedoo AG	CH	●
WIODALL BIOANALYSIS	FR	
WEP Clinical	UK	
Werchota.ai	DE	
Wespi & Partner	CH	
Wessence Language Lab	AR	
West Pharma Services	IE	
WExecutive	CH	
White Raven	BE	
Wiebecke Consulting	CH	
Willuhn Consulting AB	SE	
Windward Bio AG	CH	●
Witt/Kieffer Schweiz AG	CH	●
WittKieffer	FR	
Women on Stage	CH	
World Economic Forum	CH	
Worldwide Clinical Trials	UK	
WuXi AppTec	CH/UK/DE	●

## Participating companies

Company	Country	
WuXi Biologics	CN/DE	
WuXi XDC	CN	
Wyss Zurich Foundation	CH	●
XCubeBio AG	CH	●
Xemperia SA	CH	●
Xenometrix AG	CH	●
XenTech	FR	
XGEN Venture SGR S.p.A.	IT	
Xilis	NL	
Xinteza USA	US	
Xlife Sciences AG	CH	●
XtalPI Technology	CN/US	
YAFO Capital (Shanghai)	UK	
Yaohai Biotechnology Beijing	CN	
Ymmunobio AG	CH	●
Yokogawa Deutschland	DE	
Yokogawa Innovation Switzerland GmbH	CH	●
Young Basile	US	
Ypso Facto Luxembourg S.A.	LU	●
Ysios Capital	ES	
YUMA Capital Partners	CH	

Company	Country	
YUMAB	DE	
Zai Lab	US	
Zasys Life Sciences	IN	
Zenas Biopharma	US	
Zenith-Tx	CH	
ZentriForce Pharma Research	DE	
Zeta CH AG	CH	●
Zeyu Capital	CH	
Zhejiang Ausun Pharmaceutical	CN	
Zug Pharma Group	CH	
Zuger Capital AG	CH	●
ZugPharmaGroup	CH	
Zuhlke	DE	
Zühlke Engineering	CH	
Zühlke Ventures	CH	
Zurich University of Applied Sciences ZHAW	CH	
ZuriEV	CH	
ZüriPharm	CH	
Zust-AI d.o.o	SI	
Zymo Research Europe GmbH	DE	

# Sponsors, exhibitors & partners

## Main sponsors



## Sponsors



# Sponsors, exhibitors & partners



## Supporting partners



## Media partners



## Host and event manager



## Logistics and marketing partner



**Save the date!**

# SWISS BIOTECH DAY 2027

**April 26-27, 2027**  
Congress Center Basel

## **Are you interested in increased visibility at the next Swiss Biotech Day?**

We offer various sponsorship opportunities designed to promote your brand, products, services and build partnerships.

Contact us to discuss your ideas!  
Meet our team today at the help desk  
or contact us at [info@swissbiotechday.ch](mailto:info@swissbiotechday.ch).



Sign in on our website at [swissbiotechday.ch](http://swissbiotechday.ch) and stay updated about any news.

Host & event manager:



Logistics & marketing partner:

**bamconn**